Bio-Rad Laboratories (BIO) 10-K 2 Mar 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Feb. 24, 2020	Jun. 30, 2019
Entity Registrant Name	BIO-RAD LABORATORIES, INC.
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Amendment Flag	false
Entity Central Index Key	0000012208
Current Fiscal Year End Date	--12-31
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Filer Category	Large Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Document Annual Report	true
Document Transition Report	false
Entity File Number	1-7928
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-1381833
Entity Address, Address Line One	1000 Alfred Nobel Drive,
Entity Address, City or Town	Hercules,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94547
City Area Code	(510)
Local Phone Number	724-7000
Entity Interactive Data Current	Yes
Common Class A [Member]
Entity Common Stock, Shares Outstanding		24,839,715
Entity Public Float			$ 6,613,310,960
Title of 12(b) Security	Class A Common Stock Par Value $0.0001 per share
Trading Symbol	BIO
Security Exchange Name	NYSE
Common Class B [Member]
Entity Common Stock, Shares Outstanding		5,085,621
Entity Public Float			$ 67,954,565
Title of 12(b) Security	Class B Common Stock Par Value $0.0001 per share
Trading Symbol	BIOb
Security Exchange Name	NYSE

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
ASSETS:
Cash and cash equivalents	$ 660,672	$ 431,526
Short-term investments	453,973	413,270
Restricted investments	5,560	5,560
Accounts receivable, less allowance for doubtful accounts	392,672	392,443
Inventories:
Raw materials	109,570	108,008
Work in process	146,131	145,051
Finished goods	298,306	330,756
Total inventories	554,007	583,815
Prepaid expenses	102,331	187,249
Other current assets	10,940	9,615
Total current assets	2,180,155	2,023,478
Property, plant and equipment:
Land and improvements	25,215	25,185
Buildings and leasehold improvements	341,598	331,563
Equipment	1,015,359	970,081
Total property, plant and equipment	1,382,172	1,326,829
Less: accumulated depreciation and amortization	(882,833)	(818,139)
Property, plant and equipment, net	499,339	508,690
Operating lease right-of-use asset	201,868	0
Goodwill, net	264,131	219,770
Purchased intangibles, net	145,525	133,123
Other investments	4,638,205	2,655,709
Other assets	79,636	70,298
Total assets	8,008,859	5,611,068
LIABILITIES AND STOCKHOLDERS' EQUITY:
Accounts payable	107,014	122,450
Accrued payroll and employee benefits	180,084	143,510
Current maturities of long-term debt	426,172	493
Income taxes payable	8,763	27,513
Other taxes payable	27,522	28,675
Current operating lease liabilities	35,365	0
Deferred revenue	33,735	26,936
Other current liabilities	86,840	101,218
Total current liabilities	905,495	450,795
Long-term debt, net of current maturities	13,579	438,937
Deferred income taxes	997,787	553,239
Operating lease liabilities	176,018	0
Other long-term liabilities	160,923	147,766
Total liabilities	2,253,802	1,590,737
Commitments and contingent liabilities
Stockholders' equity:
Preferred stock	0	0
Additional paid-in capital	410,020	394,342
Retained earnings	5,470,779	3,722,073
Accumulated other comprehensive (loss) income	(87,348)	(46,958)
Total stockholders' equity	5,755,057	4,020,331
Total liabilities and stockholders' equity	8,008,859	5,611,068
Common Class A [Member]
Stockholders' equity:
Common stock	2	2
Common Class B [Member]
Stockholders' equity:
Common stock	1	1
Treasury Class-A [Member]
Stockholders' equity:
Treasury Stock, Value	(38,397)	(49,040)
Treasury Class B [Member]
Stockholders' equity:
Treasury Stock, Value	$ 0	$ (89)

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Allowance for doubtful accounts	$ 20,205	$ 26,713
Preferred stock par value	$ 0.0001	$ 0.0001
Preferred stock authorized	7,500,000	7,500,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0
Common Class A [Member]
Common stock par value	$ 0.0001	$ 0.0001
Common stock authorized	80,000,000	80,000,000
Common stock issued	24,966,035	24,884,265
Common stock outstanding	24,835,804	24,704,772
Common Class B [Member]
Common stock par value	$ 0.0001	$ 0.0001
Common stock authorized	20,000,000	20,000,000
Common stock issued	5,089,532	5,096,421
Common stock outstanding	5,089,532	5,095,504
Treasury Class-A [Member]
Treasury Stock, Shares	130,231	179,493
Treasury Class B [Member]
Treasury Stock, Shares	0	917

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Net sales	$ 2,311,659	$ 2,289,415	$ 2,160,153
Cost of Goods and Services Sold	1,054,663	1,066,264	972,450
Gross Profit	1,256,996	1,223,151	1,187,703
Selling, general and administrative expense	824,625	834,783	806,790
Research and development expense	202,710	199,196	250,157
Impairment losses on goodwill and long-lived assets	0	292,513	11,506
Income from operations	229,661	(103,341)	119,250
Interest expense	23,416	23,962	23,014
Foreign exchange losses, net	2,245	2,861	9,128
Unrealized Gain on Securities	(2,030,987)	(606,230)	0
Other (income) expense, net	(26,094)	(36,593)	(10,697)
Income before income taxes	2,261,081	512,659	97,805
Provision for income taxes	(502,406)	(147,045)	24,444
Net Income (Loss) Attributable to Parent	$ 1,758,675	$ 365,614	$ 122,249
Basic earnings per share:
Earnings Per Share, Basic	$ 58.93	$ 12.25	$ 4.12
Weighted average common shares - basic	29,843	29,836	29,655
Diluted earnings per share:
Earnings Per Share, Diluted	$ 58.27	$ 12.10	$ 4.07
Weighted average common shares - diluted	30,184	30,228	30,034

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Cash received from customers	$ 2,311,925	$ 2,326,310	$ 2,093,948
Cash paid to suppliers and employees	(1,818,575)	(1,989,685)	(1,916,119)
Interest paid, net	(22,330)	(22,703)	(22,224)
Income tax payments, net	(45,081)	(62,414)	(52,136)
Investment proceeds and miscellaneous receipts, net	31,673	26,383	18,392
Proceeds from (payments for) forward foreign exchange contracts, net	285	7,603	(17,724)
Net cash provided by operating activities	457,897	285,494	104,137
Cash flows from investing activities:
Capital expenditures	(98,532)	(129,825)	(111,332)
Proceeds from dispositions of property, plant and equipment	129	4,315	86
Proceeds from divestiture of a product line	0	6,964	0
Payments for (proceeds from) acquisitions and long-term investment	(79,386)	266	(76,645)
Recovery of (payments for) purchases of intangible assets	(8,818)	3	3,795
Payments for purchases of restricted investment	0	0	(1,000)
Payments for purchases of marketable securities and investments	(371,450)	(371,019)	(282,656)
Proceeds from sales of marketable securities and investments	104,632	77,029	97,523
Proceeds from maturities of marketable securities and investments	226,900	225,295	202,247
Net cash used in investing activities	(208,889)	(186,978)	(175,572)
Cash flows from financing activities:
Net (payments) borrowings on line-of-credit arrangements and notes payable	0	0	(36)
Payments on long-term borrowings	(643)	(2,961)	(316)
Payments for credit agreement renewal fees	(486)	0	0
Proceeds from Issuances of common stock for shared-based compensation	13,113	14,133	14,604
Tax payments from net share settlement	(8,096)	(8,862)	(7,310)
Proceeds from reissuances of treasury stock for shared-based compensation, net	3,831	0	0
Payments for purchases of treasury stock	(28,000)	(48,912)	(2,920)
Payments of contingent consideration	(2,477)	(2,078)	(3,681)
Net cash (used in) provided by financing activities	(22,758)	(48,680)	341
Effect of foreign exchange rate changes on cash	2,237	(655)	(1,094)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect	228,487	49,181	(72,188)
Beginning Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	434,164	384,983	457,171
Cash and cash equivalents	660,672	431,526	383,824
Restricted Cash included in Other current assets	93	111	882
Restricted Cash included in Other assets	1,886	2,527	277
Ending Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 662,651	$ 434,164	$ 384,983

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]
Balance at Dec. 31, 2016	$ 2,579,160	$ 3	$ 332,911	$ (101)	$ 1,828,581	$ 417,766
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	122,249				122,249
Other comprehensive income, net of tax	200,893					200,893
Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect					(120,135)	120,135
Issuance of common stock	4,490		4,490
Stock compensation expense	23,439		23,439
Treasury Stock, Value, Acquired, Cost Method	(2,920)			(2,920)
Stock Issued During Period, Value, Treasury Stock Reissued	2,804			2,804
Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net	135		391		(256)
Balance at Dec. 31, 2017	2,930,250	3	361,231	(217)	1,830,439	738,794
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	365,614				365,614
Other comprehensive income, net of tax	(106,495)					(106,495)
Issuance of common stock	5,271		5,271
Stock compensation expense	27,840		27,840
Treasury Stock, Value, Acquired, Cost Method	(48,912)			(48,912)
Balance at Dec. 31, 2018	4,020,331	3	394,342	(49,129)	3,722,073	(46,958)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity Securities without Readily Determinable Fair Value, Amount	600
Net income	1,758,675				1,758,675
Other comprehensive income, net of tax	(40,390)					(40,390)
Issuance of common stock	5,017		5,017
Stock compensation expense	35,593		35,593
Treasury Stock, Value, Acquired, Cost Method	(28,000)			(28,000)
Stock Issued During Period, Value, Treasury Stock Reissued	3,831		(24,932)	38,732	(9,969)
Balance at Dec. 31, 2019	5,755,057	$ 3	$ 410,020	$ (38,397)	$ 5,470,779	$ (87,348)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity Securities without Readily Determinable Fair Value, Amount	$ 300

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Net Income (Loss) Attributable to Parent	$ 1,758,675	$ 365,614	$ 122,249
Foreign currency translation adjustments	(36,953)	(112,857)	76,050
Other post-employment benefits adjustments, net of tax	(7,363)	7,549	(3,767)
Net unrealized holding gains on available-for-sale investments, net of tax	3,926	(1,187)	248,745
Other comprehensive income, net of tax	(40,390)	(106,495)	321,028
Comprehensive income attributable to Bio-Rad	$ 1,718,285	$ 259,119	$ 443,277

1. Significant Accounting Polic

1. Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies	1. SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of intercompany balances and transactions. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued. The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading. To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects for those events and conditions. Cash and Cash Equivalents Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less which are readily convertible into cash. Cash equivalents are stated at cost, which approximates fair value. Short-term Restricted Investments Short-term restricted investments of $5.6 million at both December 31, 2019 and 2018 represent a money market fund that is renewed annually for collateral that secures worker's compensation and general liability insurance. Investment income accrues to Bio-Rad and is recorded in Cash and cash equivalents in the Consolidated Balance Sheets. Available-for-Sale Investments Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities, U.S. government sponsored agencies and marketable equity securities. Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date. Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations. Available-for-sale investments are reported at fair value based on quoted market prices and other observable market data. Unrealized gains and losses are reported as a component of other comprehensive income, net of any related tax effect. Effective January 1, 2018, changes in fair value for equity securities are reported in Change in fair market value of equity securities in the Consolidated Statements of Income due to the adoption of ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Unrealized losses are charged against income when a decline in the fair value of an individual security is determined to be other-than-temporary. We review our available-for-sale debt securities for other-than-temporary losses on a quarterly basis. Realized gains and losses and other-than-temporary impairments on investments are included in Other (income) expense, net (see Note 10). Concentration of Credit Risk Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, investments, foreign exchange contracts and trade accounts receivable. Cash and cash equivalents and investments are placed with various highly rated major financial institutions located in different geographic regions. The forward contracts used in managing our foreign currency exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements. We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated domestic and international financial institutions. In the event of non-performance by these counterparties, the carrying values of our financial instruments represent the maximum amount of loss we would have incurred as of our fiscal year-end. We perform credit evaluation procedures related to our trade receivables and with the exception of certain developing countries, generally do not require collateral. As a result of increased risk in certain developing countries, some Bio-Rad sales are subject to collateral letters of credit from our customers. Credit risk for trade accounts receivable is generally limited due to the large number of customers and their dispersion across many geographic areas. However, a significant amount of trade receivables are with national healthcare systems in countries within the European Union. Accounts Receivable We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. The amount of the allowance is determined by analyzing known uncollectible accounts, aged receivables, economic conditions in the customers’ country or industry, historical losses and our customers’ credit-worthiness. Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance. Inventory Inventories are valued at the lower of cost and net realizable value and include material, labor and overhead costs. The first-in, first-out method is used to relieve inventory for products sold. Property, Plant and Equipment Property, plant and equipment are carried at cost, less accumulated depreciation and amortization. Included in property, plant and equipment are buildings and equipment acquired under capital lease arrangements, reagent rental equipment and capitalized software, including costs for software developed or obtained for internal use. Property, plant and equipment are assessed for impairment quarterly or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets. The estimated useful lives of property, plant and equipment are generally as follows: buildings and leasehold improvements, 10 - 39 years or the term of the leases or life of the improvements, whichever is shorter; reagent rental equipment, 1 - 5 years; and equipment, 3 - 12 years. Leases We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use (“ROU”) assets, Current operating lease liabilities, and Operating lease liabilities in our Consolidated Balance Sheet as of December 31, 2019 . Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities in our Consolidated Balance Sheet as of December 31, 2019 . ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Where we act as lessee, we elected not to separate lease and non-lease components. Where we act as lessor in our reagent rental arrangements, we allocate the consideration in the contract to the separate lease components and non-lease components. After allocation, the amount of variable payments allocated to lease components will be recognized as income under the lease accounting standard ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Such reagent rental arrangements are more fully described below under the caption "Reagent Rental Agreements." Goodwill Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of acquired businesses. Goodwill is assessed for impairment by applying fair value based tests annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We perform impairment tests of goodwill at our reporting unit level, which is one level below our operating segments. Our reporting units are identified as components for which discrete financial information is available and is regularly reviewed by management. Goodwill amounts are assigned to reporting units at the time of acquisition. The goodwill impairment amount will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. We use a projected discounted cash flow model to determine the fair value of a reporting unit. Long-Lived Assets For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. We assess the impairment of long-lived assets (including identifiable intangible assets and operating lease right-of-use assets) quarterly or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors that we consider important that could trigger an impairment review include: • significant under-performance relative to expected, historical or projected future operating results; • significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our overall business; • a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of at a loss before the end of its previously estimated useful life; and • significant negative industry, legal, regulatory or economic trends. When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method. Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets. We estimate the future cash flows of the long-lived assets using current and long-term financial forecasts. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If this is the case, an impairment loss would be recognized. The impairment loss recognized is the amount by which the carrying amount exceeds the fair value. Income Taxes We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities reflect the tax effects of net operating losses, tax credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. They are determined using enacted tax rates in effect for the year in which such temporary differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. We record deferred tax assets to the extent we believe these assets will more likely than not be realized. In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. When we establish, or reduce the valuation allowance against our deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period that determination to change the valuation allowance is made. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than a 50% likelihood of being realized upon settlement. The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in the provision for income taxes. On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The Tax Act made broad and complex changes to the U.S. tax code, including the imposition of a one-time mandatory deemed repatriation tax (“Transition Tax”) on certain earnings accumulated offshore since 1986 and the reduction of the corporate tax rate from 35% to 21% for U.S. taxable income, resulting in a one-time remeasurement of U.S. federal deferred tax assets and liabilities. In 2017, we recorded an income tax benefit of $70 million related to the Transition Tax and remeasurement of our U.S. federal deferred tax assets and liabilities. We completed our accounting for the Tax Act under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) in 2018, which resulted in an additional income tax benefit of $49 million . Revenue Recognition On January 1, 2018, we adopted Accounting Standards Codification ("ASC") 606, "Revenue from Contracts with Customers," using the modified retrospective method applied to those contracts that were not completed as of January 1, 2018. We recorded a net reduction to opening retained earnings of $0.1 million as of January 1, 2018 due to the cumulative impact of adopting ASC 606 with the impact primarily related to a customer loyalty program in the United States for which the resulting non-cash consideration is treated as variable consideration under the new revenue recognition accounting standard. We recognize revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment, and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service. At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, transaction prices are allocated to performance obligations based on stand-alone selling prices. The method used to determine the stand-alone selling prices for service revenues is based on the observable prices when the services have been sold separately. In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance. We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. Reagent Rental Agreements Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at lease commencement. Where we have determined that such an arrangement contains a lease, we next must ascertain its lease classification for purposes of applying appropriate accounting treatment as an operating, sales-type or direct financing lease. In addition, for purposes of determining the lease term used in performing the lease classification test, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if the customer is reasonably certain to exercise that option, the periods covered by an option to terminate the lease if the customer is reasonably certain not to exercise that option, and the periods covered by the option to extend (or not to terminate) the lease in which exercise of the option is controlled by the company. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel, the period in which the contract is enforceable is a very short period and therefore the lease term has been limited to the noncancellable period. Furthermore, it has historically been very rare for these arrangements to contain an option for the lessee to purchase the underlying asset. As discussed further above under the caption “Leases” and below under the caption “Recent Accounting Pronouncements Adopted,” as well as in Note 16, Leases, we adopted ASC 842, “Leases,” on a modified retrospective basis effective January 1, 2019 with practical expedients, and did not restate comparative prior periods. We concluded that the use of the instrument (referred to as “lease elements”) is not within the guidance of ASC 606 but rather ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After allocation, the amount of variable payments allocated to lease components will be recognized as income under ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Upon our adoption of ASC 842 in 2019, the maintenance services, along with the reagents, are now allocated to the non-lease elements and will be recognized as income in accordance with ASC 606. This change is in alignment with the requirements of ASC 842, and has resulted in a decrease in the amount of rental income and a corresponding increase in the amount of maintenance service revenue that is included in total reported Net sales in our consolidated income statements. Generally, the terms of the arrangements result in the transfer of control on reagents upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer. Historically, our reagent rental arrangements have been predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as very few of such arrangements contain any fixed/minimum lease payments. As a result, our lease income is heavily variable in nature. Further, our reagent rental arrangements are predominantly classified as operating leases, and any sales-type leases represent in aggregate a very insignificant amount of lease income. Hence, our reported lease income is primarily variable in nature and is recognized as the reagents are consumed by the customer or delivered. Revenue allocated to the lease elements of these reagent rental arrangements represents approximately 3% and 5% of total revenue for 2019 and 2018 , respectively, and is included as part of the Net sales in our Consolidated Statements of Income. Contract costs: As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities. Disaggregation of Revenue: The disaggregation of our revenue by geographic region based primarily on the location of the use of the product service, and by industry segment sources, and the disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 14). Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are generally recognized ratably over the term of the service contract as our performance extends over the life of the arrangement. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The increase in our total deferred revenue balance from $37.3 million at December 31, 2018 to $45.8 million at December 31, 2019 was primarily driven by $33.1 million , net, of cash payments received or due in advance of satisfying our performance obligations, partially offset by $24.6 million of revenue recognized that were included in our deferred revenue balance as of December 31, 2018 . We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback. A review is performed on a quarterly basis to assess the adequacy of our warranty accrual. Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Consolidated Balance Sheets, were as follows (in millions): 2019 2018 January 1 $ 10.1 $ 18.7 Provision for warranty 9.9 25.5 Actual warranty costs (11.0 ) (34.1 ) December 31 $ 9.0 $ 10.1 Shipping and Handling We classify all freight costs billed to customers as Net sales. Related freight costs are recognized upon transfer of control of the promised products to customers as a fulfillment cost and included in Cost of goods sold. Research and Development Internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed. We conduct extensive research and development activities in all areas of our business, employing approximately 780 employees worldwide in these activities, including degreed scientists and technical support staff. Research and development has played a major role in Bio-Rad’s growth and is expected to continue to do so in the future. Our research teams are continuously developing new products and new applications for existing products. In our development of new products and applications, we interact with scientific and medical professionals at universities, hospitals and medical schools, and within our industry. Foreign Currency Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period. Income statement items are translated at average exchange rates for the period. The resulting translation adjustments are recorded as a separate component of stockholders’ equity. Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the Consolidated Statements of Income. Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction. Forward Foreign Exchange Contracts As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded as an asset or liability measured at their fair value at each balance sheet date. The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all of which are recorded in Foreign exchange losses, net in the Consolidated Statements of Income. Share-Based Compensation Plans Share-based compensation expense for all share-based payment awards granted is determined based on the grant-date fair value. We recognize these compensation costs over the requisite service period of the award, which is generally the vesting term of the share-based payment awards. Forfeitures are recognized as they occur. These plans are described more fully in Note 9. Earnings Per Share Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period. Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding. Potential common shares are excluded from the diluted earnings per share calculation if the effect would be anti-dilutive. The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands): Year Ended December 31, 2019 2018 2017 Basic weighted average shares outstanding 29,843 29,836 29,655 Effect of potentially dilutive stock options and restricted stock awards 341 392 379 Diluted weighted average common shares 30,184 30,228 30,034 Anti-dilutive stock options and restricted stock awards excluded from the computation of diluted EPS 98 84 13 Fair Value of Financial Instruments For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts approximate fair value. The estimated fair value of financial instruments is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) using available market information or other appropriate valuation methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value. The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value (see Note 3). Recent Accounting Pronouncements Adopted In August 2018, the FASB issued ASU 2018-15, "Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract." ASU 2018-15 amends the definition of a hosting arrangement and requires a customer in a hosting arrangement that is a service contract to capitalize certain implementation costs as if the arrangement was an internal-use software project. The internal-use software guidance states that only qualifying costs incurred during the application development stage can be capitalized. We prospectively adopted ASU 2018-15 effective January 1, 2019. As of December 31, 2019 , we capitalized $3.1 million of implementation costs for cloud computing arrangements, net of accumulated amortization, primarily for business analytics software. These costs were recorded in Other current assets and Other assets in the Consolidated Balance Sheet. In August 2018, the SEC issued Final Rule Release No. 33-10532, "Disclosure Update and Simplification" that extends to interim periods the annual disclosure requirement of presenting the changes in stockholders' equity, which was effective in the first quarter of 2019. In February 2016, the FASB issued ASU 2016-02, "Leases," and related accounting standard updates, which requires, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures are enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. We

2. Acquisitions

2. Acquisitions	12 Months Ended
	Dec. 31, 2019
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	2. ACQUISITIONS In October 2019, we acquired all the issued and outstanding shares of a foreign distributor for approximately $4.2 million , which included cash payments at closing, net of closing cash, of $3.6 million , and $0.6 million in contingent consideration potentially payable to the sellers. In addition, we recorded a net gain of $0.4 million for the settlement of preexisting conditions concurrent with the acquisition that was recorded in Selling, general and administrative expense. The acquisition was included in our Clinical Diagnostics segment's results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. Proforma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented. As of December 31, 2019 , the preliminary allocation of the payments was $3.4 million to customer relationships; a definite-lived intangible, $0.2 million to deferred tax asset, $0.8 million to deferred tax liability related to the purchased intangible and $1.4 million to acquired net assets. In August 2019, we acquired all the issued and outstanding membership interests of Exact Diagnostics, LLC for approximately $60.0 million . Cash payments at closing, net of closing cash, were $59.7 million . The acquisition was included in our Clinical Diagnostics segment's results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is deductible for income tax purposes. Proforma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented. The final allocation of the payments was $26.8 million to purchased intangibles consisting primarily of customer relationships, developed product technology and tradenames, $4.2 million to acquired net assets, and $28.7 million to goodwill. We believe that the acquisition will accelerate market penetration in the areas of quality controls and assay verification panels in our Clinical Diagnostics operations. In March 2019, we completed the acquisition of all the issued and outstanding stock of a small U.S. private company for approximately $20.0 million . Cash payments, net of closing cash, consisted of $4.0 million paid in November 2018 and the remaining $16.0 million paid in March 2019. The acquisition was included in our Life Science segment's results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is not deductible for income tax purposes. Pro forma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented. The final allocation of the payments was $15.6 million to goodwill that included workforce and time-to-market advantage, $5.5 million to definite-lived intangibles, $0.2 million to in-process research and development, an indefinite-lived intangible asset, and a deferred tax liability of $1.3 million related to the purchased intangibles. We believe that the acquisition will expand our reagents suite of offerings in our Life Science operations.

3. Fair Value Measurements

3. Fair Value Measurements	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. FAIR VALUE MEASUREMENTS We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows: • Level 1: Quoted prices in active markets for identical instruments • Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments) • Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments) Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2019 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 42.9 $ — $ 42.9 Time deposits 31.2 10.0 — 41.2 Asset-backed securities — 0.1 — 0.1 Money market funds 69.9 — — 69.9 Total cash equivalents (a) 101.1 53.0 — 154.1 Restricted investment 5.6 — — 5.6 Equity Securities (b) 4,664.4 — — 4,664.4 Available-for-sale investments: Corporate debt securities — 204.5 — 204.5 U.S. government sponsored agencies — 106.1 — 106.1 Foreign government obligations — 4.7 — 4.7 Other foreign obligations — 3.1 — 3.1 Municipal obligations — 11.6 — 11.6 Asset-backed securities — 72.9 — 72.9 Total available-for-sale investments (c) — 402.9 — 402.9 Forward foreign exchange contracts (d) — 0.9 — 0.9 Total financial assets carried at fair value $ 4,771.1 $ 456.8 $ — $ 5,227.9 Financial liabilities carried at fair value: Forward foreign exchange contracts (e) $ — $ 1.0 $ — $ 1.0 Contingent consideration (f) — — 4.9 4.9 Total financial liabilities carried at fair value $ — $ 1.0 $ 4.9 $ 5.9 Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2018 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 77.8 $ — $ 77.8 Time deposits 22.7 10.0 — 32.7 Asset-backed securities — 0.3 — 0.3 Money market funds 36.9 — — 36.9 Total cash equivalents (a) 59.6 88.1 — 147.7 Restricted investment: 5.6 — — 5.6 Equity securities (b) 2,672.9 — — 2,672.9 Available-for-sale investments: Corporate debt securities — 215.0 — 215.0 U.S. government sponsored agencies — 80.3 — 80.3 Foreign government obligations — 3.6 — 3.6 Municipal obligations — 11.0 — 11.0 Asset-backed securities — 63.3 — 63.3 Total available-for-sale investments (c) — 373.2 — 373.2 Forward foreign exchange contracts (d) — 0.6 — 0.6 Total financial assets carried at fair value $ 2,738.1 $ 461.9 $ — $ 3,200.0 Financial liabilities carried at fair value: Forward foreign exchange contracts (e) $ — $ 0.7 $ — $ 0.7 Contingent consideration (f) — — 8.4 8.4 Total financial liabilities carried at fair value $ — $ 0.7 $ 8.4 $ 9.1 (a) Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets. (b) Equity securities are included in the following accounts in the Consolidated Balance Sheets (in millions): December 31, 2019 December 31, 2018 Short-term investments $ 51.0 $ 40.2 Other investments 4,613.4 2,632.7 Total $ 4,664.4 $ 2,672.9 The year-to-date unrealized gains on our equity securities still held as of December 31, 2019 were $2,031.1 million and were primarily due to our investment in Sartorius AG and are recorded in our Consolidated Statements of Income. (c) Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions): December 31, December 31, 2018 Short-term investments $ 402.8 $ 373.0 Other investments 0.1 0.2 Total $ 402.9 $ 373.2 (d) Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets. (e) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets. (f) Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions): December 31, 2019 December 31, 2018 Other current liabilities $ 3.3 $ 3.2 Other long-term liabilities 1.6 5.2 Total $ 4.9 $ 8.4 During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel Labs. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020. The sales milestones could potentially range from $0 to an unlimited amount. In the first and third quarters of 2019, we paid $1.4 million and $1.1 million , respectively, per the purchase agreement. Since 2016 we have had a net decrease in the cumulative valuation of the sales milestones of $13.9 million . The contingent consideration was accrued at its estimated fair value of $4.3 million as of December 31, 2019 . During the fourth quarter of 2019, we recognized a contingent consideration liability for earn-out targets related to our acquisition of a foreign distributor. The first earn-out payment of $0.7 million was paid by the acquisition date and the remaining payment is due in the second quarter of 2020. The maximum earn-out payment due is $1.4 million . The contingent consideration was accrued at its estimated fair value of $0.6 million as of December 31, 2019 . The following table provides a reconciliation of the Level 3 contingent consideration liabilities measured at estimated fair value (in millions): December 31, 2018 $ 8.4 Analytical flow cytometer platform: Payment of sales milestone (2.5 ) Net decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense (1.6 ) Foreign distributor earn-outs: Acquisition of foreign distributor $ 0.6 December 31, 2019 $ 4.9 The following table provides q ua ntitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of December 31, 2019 . Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement. Valuation Technique Unobservable Input Percentage Analytical flow cytometer platform Probability-weighted income approach Sales milestones: Discount rate 11.1 % Cost of debt 3.9 % To estimate the fair value of Level 2 debt securities, our primary pricing provider used Reuters as of December 31, 2019 and Securities Evaluations as of December 31, 2018 as the primary pricing sources. Our pricing process allowed us to select a hierarchy of pricing sources for securities held. If Reuters or Securities Evaluations did not price a Level 2 security that we held, then the pricing provider utilized our custodian supplied pricing as the secondary pricing source. For all commercial paper as of December 31, 2019 , our primary pricing provider used its leading pricing source in the hierarchy to determine pricing. Our primary pricing provider performed daily reasonableness testing of the Reuters and Securities Evaluations prices. Price changes of 5% or greater were investigated and resolved. In addition, we performed a quarterly testing of the Reuters and Securities Evaluations prices to custodian reported prices. Price differences outside a tolerable variance of approximately 1% were investigated and resolved. Available-for-sale investments consist of the following (in millions): December 31, 2019 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Short-term investments: Corporate debt securities $ 203.2 $ 1.4 $ (0.1 ) $ 204.5 Municipal obligations 11.5 0.1 — 11.6 Asset-backed securities 72.7 0.2 (0.1 ) 72.8 U.S. government sponsored agencies 105.6 0.7 (0.2 ) 106.1 Foreign government obligations 4.7 — — 4.7 Other foreign obligations 3.1 — — 3.1 400.8 2.4 (0.4 ) 402.8 Long-term investments: Asset-backed securities 0.1 — — 0.1 0.1 — — 0.1 Total $ 400.9 $ 2.4 $ (0.4 ) $ 402.9 The following is a summary of the amortized cost and estimated fair value of our debt securities at December 31, 2019 by contractual maturity date (in millions): Amortized Cost Estimated Fair Value Mature in less than one year $ 174.5 $ 174.6 Mature in one to five years 164.2 165.2 Mature in more than five years 62.2 63.1 Total $ 400.9 $ 402.9 Available-for-sale investments consist of the following (in millions): December 31, 2018 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Short-term investments: Corporate debt securities $ 216.2 $ 0.1 $ (1.3 ) $ 215.0 Municipal obligations 11.1 — (0.1 ) 11.0 Asset-backed securities 63.5 — (0.4 ) 63.1 U.S. government sponsored agencies 80.9 0.2 (0.8 ) 80.3 Foreign government obligations 3.6 — — 3.6 375.3 0.3 (2.6 ) 373.0 Long-term investments: Asset-backed securities 0.2 — — 0.2 0.2 — — 0.2 Total $ 375.5 $ 0.3 $ (2.6 ) $ 373.2 The following is a summary of investments with gross unrealized losses and the associated fair value (in millions): December 31, December 31, 2018 Fair value of investments in a loss position 12 months or more $ 19.9 $ 117.9 Fair value of investments in a loss position less than 12 months $ 97.8 $ 193.0 Gross unrealized losses for investments in a loss position 12 months or more $ 0.1 $ 1.8 Gross unrealized losses for investments in a loss position less than 12 months $ 0.3 $ 0.8 The unrealized losses on these securities are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others. Because Bio-Rad has the ability and intent to hold these investments with unrealized losses until a recovery of fair value, or for a reasonable period of time sufficient for a forecasted recovery of fair value, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at December 31, 2019 or at December 31, 2018 . As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date. The notional principal amounts provide one measure of the transaction volume outstanding as of December 31, 2019 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties. The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign exchange losses, net in the Consolidated Statements of Income. The following is a summary of our forward foreign currency exchange contracts (in millions): December 31, 2019 Contracts maturing in January through March 2020 to sell foreign currency: Notional value $ 52.0 Unrealized gain $ 0.3 Contracts maturing in January through March 2020 to purchase foreign currency: Notional value $ 269.1 Unrealized loss $ (0.3 ) The estimated fair value of our current maturities of long-term debt, excluding leases, as of December 31, 2019 and long-term-debt, excluding all lease and current maturities, as of December 31, 2018 that is not recognized at fair value in the Consolidated Balance Sheets has an estimated fair value based on quoted market prices for the same or similar issues. The estimated fair value of our debt discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions): December 31, 2019 December 31, 2018 Carrying Amount Estimated Fair Value Fair Value Hierarchy Level Carrying Amount Estimated Fair Value Fair Value Hierarchy Level Total current maturities long-term debt, excluding leases $ 424.4 $ 435.5 2 $ — $ — 2 Total long-term debt, excluding leases and current maturities $ — $ — 2 $ 423.7 $ 435.8 2 Included in Other Investments in the Consolidated Balance Sheet are investments without readily determinable fair value measured at cost with adjustments for observable price changes in price or impairments. The carrying value of these investments was $0.3 million and $0.6 million as of December 31, 2019 and December 31, 2018 , respectively. We own shares of ordinary voting stock of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own over 37% of the outstanding voting shares (excluding treasury shares) of Sartorius as of December 31, 2019 . The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius' board of directors, nor do we have the ability to exercise significant influence over the operating and financial policies of Sartorius. As of December 31, 2019 , due to the adoption of ASU 2016-01 and ASU 2018-03 as of January 1, 2018 , we account for this investment at fair market value as determined at period end by a quoted price on an organized exchange.

4. Intangible Assets, Goodwill

4. Intangible Assets, Goodwill and Other	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure	4. GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS Changes to goodwill by segment were as follows (in millions): 2019 2018 Life Clinical Total Life Clinical Total Balances as of January 1: Goodwill $ 234.5 $ 320.5 $ 555.0 $ 234.7 $ 324.6 $ 559.3 Accumulated impairment losses and write-offs (41.8 ) (293.4 ) (335.2 ) (35.9 ) (17.3 ) (53.2 ) Goodwill, net 192.7 27.1 219.8 198.8 307.3 506.1 Acquisitions 15.6 28.7 44.3 — — — Divestiture — — — — (1.4 ) (1.4 ) Impairment — — — (5.9 ) (276.1 ) (282.0 ) Currency fluctuations — — — (0.2 ) (2.7 ) (2.9 ) Balances as of December 31: Goodwill 250.1 349.2 599.3 234.5 320.5 555.0 Accumulated impairment losses and write-offs (41.8 ) (293.4 ) (335.2 ) (41.8 ) (293.4 ) (335.2 ) Goodwill, net $ 208.3 $ 55.8 $ 264.1 $ 192.7 $ 27.1 $ 219.8 In conjunction with the purchase of all the issued and outstanding shares of a foreign distributor in October 2019 (see Note 2, "Acquisitions"), we recorded $3.4 million of Customer relationships, a definite-lived intangible assets. In conjunction with the purchase of all the issued and outstanding membership interests of Exact Diagnostics, LLC in August 2019 (see Note 2, "Acquisitions"), we recorded $28.7 million of goodwill and $26.8 million of definite-lived intangible assets: $16.1 million of Customer relationships, $8.1 million of Developed product technology, $2.5 million of Tradenames and $0.1 million of Backlog. In conjunction with the purchase of all the issued and outstanding stock of a small U.S. private company in March 2019 (see Note 2, "Acquisitions"), we recorded $15.6 million of goodwill that included workforce and time-to-market advantage, $5.5 million of Developed product technology, a definite-lived intangible asset, and $0.2 million of In-process research and development, an indefinite-lived intangible asset. In March 2018, we wrote off $1.4 million of goodwill from our Clinical Diagnostics segment as a result of a divestiture of a product line. In 2018, we impaired goodwill associated with our 1999 acquisition of Pasteur Sanofi Diagnostics S.A., 2007 through 2012 acquisitions of DiaMed Holding AG, DiaMed Fennica Oy, DiaMed (G.B.) Limited, and DiaMed Benelux (collectively DiaMed), 2010 acquisition of Biotest AG, and 2013 acquisition of AbD Serotec in the amounts of $18.1 million , $247.2 million , $10.8 million and $5.9 million , respectively. Goodwill for DiaMed, Biotest AG and AbD Serotec was fully impaired at December 31, 2018. Impairments for the Pasteur Sanofi Diagnostics S.A., DiaMed and Biotest AG were included in our Clinical Diagnostics segment's results of operations, and the impairment for AbD Serotec was included in our Life Science segment's results of operations. The impairments were based upon a revision of our Level 3 valuation inputs, i.e., expected future cash flows. Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions): December 31, 2019 Weighted-Average Amortization Period (years) Purchase Price Accumulated Amortization Net Carrying Amount Customer relationships/lists 6.36 $ 107.2 $ (74.3 ) $ 32.9 Know how 5.71 188.5 (162.6 ) 25.9 Developed product technology 8.31 144.2 (93.9 ) 50.3 Licenses 8.74 76.0 (44.4 ) 31.6 Tradenames 8.50 6.4 (3.6 ) 2.8 Covenants not to compete 6.01 3.2 (1.4 ) 1.8 Other — 0.1 (0.1 ) — Total definite-lived intangible assets 525.6 (380.3 ) 145.3 In-process research and development 0.2 — 0.2 Total purchased intangible assets $ 525.8 $ (380.3 ) $ 145.5 December 31, 2018 Weighted-Average Amortization Period (years) Purchase Price Accumulated Amortization Net Carrying Amount Customer relationships/lists 3.98 $ 88.7 $ (68.3 ) $ 20.4 Know how 6.64 190.6 (159.8 ) 30.8 Developed product technology 8.34 130.4 (86.6 ) 43.8 Licenses 9.72 76.3 (40.9 ) 35.4 Tradenames 3.42 3.9 (3.3 ) 0.6 Covenants not to compete 7.01 3.2 (1.1 ) 2.1 Total definite-lived intangible assets $ 493.1 $ (360.0 ) $ 133.1 In 2018, we impaired developed product technology and fully impaired covenants not to compete in the amounts of $8.8 million and $1.7 million , respectively, associated with our 2012 acquisition of a cell sorting system from Propel Labs, Inc. These impairments were included in our Life Science segment's results of operations. The impairments were based upon a revision of our Level 3 valuation inputs, i.e., expected future cash flows. Amortization expense related to purchased intangible assets for the years ended December 31, 2019 , 2018 and 2017 was $23.5 million , $28.3 million and $30.8 million , respectively. Estimated future amortization expense (based on existing purchased intangible assets) for the years ending December 31, 2020 , 2021 , 2022 , 2023 , 2024 and thereafter is $23.5 million , $22.8 million , $19.6 million , $18.7 million , $16.6 million , and $44.1 million , respectively.

5. Notes Payable and Long-Term

5. Notes Payable and Long-Term Debt	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Notes Payable and Long-term Debt	5. NOTES PAYABLE AND LONG-TERM DEBT Under domestic and international lines of credit, standby letters of credit and guarantee arrangements, we had $207.5 million available for borrowing and usage as of December 31, 2019 , which was reduced by $4.2 million that was utilized for standby letters of credit and guarantee arrangements issued by our banks to support our obligations. The principal components of long-term debt are as follows (in millions): December 31, 2019 December 31, 2018 4.875% Senior Notes due 2020, net of discount $ 425.0 $ 425.0 Less unamortized discount and debt issuance costs (0.6 ) (1.3 ) Long-term debt less unamortized discount and debt issuance costs 424.4 423.7 Finance leases and other debt 15.4 — Capital leases and other debt — 15.7 439.8 439.4 Less current maturities (426.2 ) (0.5 ) Long-term debt $ 13.6 $ 438.9 Senior Notes due 2020 In December 2010, Bio-Rad sold $425.0 million principal amount of Senior Notes due December 2020 ( 4.875% Notes). The sale yielded net cash proceeds of $422.6 million at an effective rate of 4.946% . The 4.875% Notes pay a fixed rate of interest of 4.875% per year. We have the option to redeem any or all of the 4.875% Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the 4.875% Notes) and accrued and unpaid interest thereon to the redemption date. Our obligations under the 4.875% Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness. Certain covenants apply at each year end to the 4.875% Notes including limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. We were in compliance with these covenants as of December 31, 2019 . There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios. Credit Agreement In April 2019, Bio-Rad entered into a $200.0 million unsecured Credit Agreement. Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of December 31, 2019 ; however, $0.2 million was utilized for domestic standby letters of credit that reduced our borrowing availability as of December 31, 2019 . The Credit Agreement matures in April 2024 . If we had borrowed against our Credit Agreement, the borrowing rate would have been 3.035% at December 31, 2019 . The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens. We were in compliance with all of these ratios and covenants as of December 31, 2019 . Maturities of long-term debt at December 31, 2019 were as follows: 2020 - $426.8 million ; 2021 - $1.6 million ; 2022 - $1.5 million ; 2023 - $0.4 million ; 2024 - $0.4 million ; and thereafter - $9.7 million .

6. Income Taxes

6. Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes [Text Block]	6. INCOME TAXES The U.S. and international components of income before taxes are as follows (in millions): Year Ended December 31, 2019 2018 2017 U.S. $ 1,034.0 $ 363.4 $ 72.8 International 1,227.1 149.3 25.0 Income before taxes $ 2,261.1 $ 512.7 $ 97.8 The provision for income taxes consists of the following (in millions): Year Ended December 31, 2019 2018 2017 Current tax expense: U.S. Federal $ 13.0 $ 8.8 $ 6.7 State 4.4 2.2 3.4 International 23.5 30.5 32.0 Current tax expense 40.9 41.5 42.1 Deferred tax expense (benefit): U.S. Federal 409.7 114.0 (69.8 ) State 24.4 6.6 4.3 International 16.1 0.3 (19.3 ) Deferred tax expense (benefit) 450.2 120.9 (84.8 ) Non-current tax expense (benefit) 11.3 (15.4 ) 18.3 Provision for (benefit from) income taxes $ 502.4 $ 147.0 $ (24.4 ) The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows: Year Ended December 31, 2019 2018 2017 U. S. statutory tax rate 21.0 % 21.0 % 35.0 % Impact of foreign operations (9.7 ) (4.1 ) 6.0 Research tax credits (0.2 ) (0.7 ) (3.8 ) Nontaxable subsidies (0.1 ) (0.2 ) (2.2 ) Goodwill impairment — 5.6 1.2 Share-based compensation (0.1 ) (1.0 ) (5.3 ) Nondeductible executive compensation 0.1 0.2 2.0 U.S. taxation of foreign income 10.3 15.5 2.7 Acquisition-related — (0.2 ) 10.1 U.S. tax reform — (9.6 ) (71.0 ) State taxes 1.0 1.7 2.9 Other (0.1 ) 0.5 (2.6 ) Provision for (benefit from) income taxes 22.2 % 28.7 % (25.0 )% On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The Tax Act made broad and complex changes to the U.S. tax code, including the imposition of a one-time mandatory deemed repatriation tax (“Transition Tax”) on certain earnings accumulated offshore since 1986 and the reduction of the corporate tax rate from 35% to 21% for U.S. taxable income, resulting in a one-time remeasurement of U.S. federal deferred tax assets and liabilities. In 2017, we recorded an income tax benefit of $70 million related to the Transition Tax and remeasurement of our U.S. federal deferred tax assets and liabilities. We completed our accounting for the Tax Act under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) in 2018, which resulted in an additional income tax benefit of $49 million . Our effective income tax rate was 22.2% , 28.7% and (25.0)% in 2019 , 2018 and 2017 , respectively. The effective tax rate for 2018 was driven by detriments due to non-deductible impairment charges and the taxation of our foreign operations, partially offset by a $49 million benefit recorded as a result of the completion of our accounting for the Tax Act under SAB 118. The effective tax rate for 2017 was driven by a $70 million benefit recorded as a provisional estimate of the accounting for the Tax Act. Many jurisdictions in which we operate have statutory tax rates that differ from the U.S. statutory tax rate of 21%. Our effective tax rate is impacted, either favorably or unfavorably, by many factors including, but not limited to the jurisdictional mix of income before tax, changes to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and generation of tax credits. Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of deferred tax assets and liabilities are as follows (in millions): December 31, 2019 2018 Deferred tax assets: Bad debt, inventory and warranty accruals $ 23.9 $ 21.7 Other post-employment benefits, vacation and other reserves 23.0 23.0 Tax credit and net operating loss carryforwards 83.7 75.3 Lease obligations 48.6 — Other 26.0 27.1 Total gross deferred tax assets 205.2 147.1 Valuation allowance (67.2 ) (70.8 ) Total deferred tax assets 138.0 76.3 Deferred tax liabilities: Property and equipment 38.4 40.1 Lease assets 46.4 — Investments and intangible assets 1,001.4 540.6 Total deferred tax liabilities 1,086.2 580.7 Net deferred tax liabilities $ (948.2 ) $ (504.4 ) The realization of deferred tax assets is dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that our California and certain foreign deferred tax assets will not be realized as of December 31, 2019 , and have maintained a valuation allowance on such deferred tax assets. The valuation allowance against our deferred tax assets in California and certain foreign jurisdictions decreased by $3.6 million in 2019 . As of December 31, 2019 , our foreign and California net operating loss carryforwards were approximately $239.0 million and $52.7 million , respectively. Of our foreign net operating losses, $124.7 million may be carried forward indefinitely. The majority of the remaining foreign net operating losses, if not utilized, will begin to expire in 2025. Our California net operating loss carryforwards, if not utilized, will begin to expire in 2028. As of December 31, 2019 , our California research tax credit carryforwards were approximately $35.7 million and may be carried forward indefinitely. Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2012 and forward for the U.S. and certain foreign jurisdictions including France, Germany, India and Switzerland. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period. The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions): 2019 2018 2017 Unrecognized tax benefits – January 1 $ 29.8 $ 54.9 $ 21.1 Additions to tax positions related to prior years 7.6 0.6 1.3 Reductions to tax positions related to prior years (0.7 ) (20.2 ) (1.0 ) Additions to tax positions related to the current year 3.0 4.6 34.8 Settlements — (6.8 ) (0.2 ) Lapse of statute of limitations (0.4 ) (1.1 ) (3.4 ) Currency translation (0.1 ) (2.2 ) 2.3 Unrecognized tax benefits – December 31 $ 39.2 $ 29.8 $ 54.9 Bio-Rad recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. Related to the unrecognized tax benefits noted above, the cumulative amount of accrued interest and penalties as of December 31, 2019 , 2018 and 2017 , respectively was $11.2 million , $9.5 million and $10.9 million . Bio-Rad accrued interest and penalties of $1.7 million , $(1.4) million , and $(0.9) million in 2019 , 2018 , and 2017 , respectively. The total unrecognized tax benefits and interest and penalties of $50.4 million in 2019 was partially offset by deferred tax assets of $1.4 million and prepaid taxes of $5.4 million , for a net amount of $43.6 million . As of December 31, 2019 , based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by approximately $2.8 million . Substantially all such amounts will impact our effective income tax rate if recognized. It is generally our intention to repatriate certain foreign earnings to the extent that such repatriations are not restricted by local laws or accounting rules, and there are no substantial incremental costs. The determination of the amount of the unrecognized deferred tax liability for foreign earnings that are indefinitely reinvested is not practicable to estimate.

7. Stockholders' Equity

7. Stockholders' Equity	12 Months Ended
	Dec. 31, 2019
Stockholders' Equity Attributable to Parent [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	7. STOCKHOLDERS' EQUITY Bio-Rad’s issued and outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock (Class B). Each share of Class A and Class B participates equally in the earnings of Bio-Rad, and is identical in all respects except as follows. Class A has limited voting rights. Each share of Class A is entitled to one tenth of a vote on most matters, and each share of Class B is entitled to one vote. Additionally, Class A stockholders are entitled to elect 25% of the Board of Directors and Class B stockholders are entitled to elect 75% of the directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares but no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares. Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder. The founders of Bio-Rad, the Schwartz family, collectively hold a majority of Bio-Rad’s voting stock. As a result, the Schwartz family is able to exercise significant influence over Bio-Rad. Changes to Bio-Rad's issued common stock shares are as follows (in thousands): Class A Shares Class B Shares Balance at January 1, 2017 24,454 5,124 B to A conversions 34 (34 ) Issuance of common stock 191 18 Balance at December 31, 2017 24,679 5,108 B to A conversions 30 (30 ) Issuance of common stock 175 18 Balance at December 31, 2018 24,884 5,096 B to A conversions 24 (24 ) Issuance of common stock 58 18 Balance at December 31, 2019 24,966 5,090 Treasury Shares In November, 2017, the Board of Directors authorized a new share repurchase program, granting Bio-Rad authority to repurchase, on a discretionary basis, up to $250.0 million of outstanding shares of our common stock. Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions. The share repurchase activity under the share repurchase program through open market transactions in 2018 and 2019 is summarized as follows: Number of Shares Purchased Weighted-Average Price per Share Total Shares Repurchased To Date Remaining Authorized Value (in millions) November 1, 2018 - November 30, 2018 178,911 $ 273.39 193,150 $ 201.1 May 1, 2019 - May 31, 2019 25,421 $ 291.70 218,571 $ 193.7 June 1, 2019 - June 30, 2019 25,977 $ 292.01 244,548 $ 186.1 August 1, 2019 - August 31, 2019 14,745 $ 339.05 259,293 $ 181.1 November 1, 2019 - November 30, 2019 22,343 $ 358.04 281,636 $ 173.1 In 2019, we used 118,910 of the repurchased shares in connection with the vesting of restricted stock units and 19,755

8. Accumulated Other Comprehens

8. Accumulated Other Comprehensive Income	12 Months Ended
	Dec. 31, 2019
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
accumulated other comprehensive income [Text Block]	8. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Accumulated other comprehensive income (loss) included in our Consolidated Balance Sheets and Consolidated Statements of Changes in Stockholders' Equity consists of the following components (in millions): Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains (losses) on available-for-sale investments Total Accumulated other comprehensive income (loss) Balances as of January 1, 2018 $ 77.4 $ (22.3 ) $ 4.4 $ 59.5 Other comprehensive (loss) income, before reclassifications (112.9 ) 6.9 (1.4 ) (107.4 ) Amounts reclassified from Accumulated other comprehensive income — 2.4 0.3 2.7 Income tax effects — (1.8 ) — (1.8 ) Other comprehensive income (loss), net of income taxes (112.9 ) 7.5 (1.1 ) (106.5 ) Balances as of December 31, 2018 $ (35.5 ) $ (14.8 ) $ 3.3 $ (47.0 ) Other comprehensive (loss) income, before reclassifications (36.5 ) (10.0 ) 4.8 (41.7 ) Amounts reclassified from Accumulated other comprehensive income — 1.5 (0.4 ) 1.1 Income tax effects (0.4 ) 1.1 (0.5 ) 0.2 Other comprehensive (loss) income, net of income taxes (36.9 ) (7.4 ) 3.9 (40.4 ) Balances as of December 31, 2019 $ (72.4 ) $ (22.2 ) $ 7.2 $ (87.4 ) The amounts reclassified out of Accumulated other comprehensive income into the Consolidated Statements of Income, with presentation location, were as follows: December 31, Components of Comprehensive income 2019 2018 Location Amortization of foreign other post-employment benefit items $ (1.5 ) $ (2.4 ) Selling, general and administrative expense Net holding gains (losses) on equity securities and available for sale investments $ 0.4 $ (0.3 ) Other (income) expense, net Reclassification adjustments are calculated using the specific identification method.

9. Share-based Compensation

9. Share-based Compensation	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement, Noncash Expense [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments	9. SHARE-BASED COMPENSATION/EQUITY AWARD AND PURCHASE PLANS Description of Share-Based Compensation Plans We believe our share-based compensation plans align the interests of our employees with those of our shareholders. Equity Award Plans We have two equity award plans for officers and certain other employees: the 2007 Incentive Award Plan (2007 Plan) and the 2017 Incentive Award Plan (2017 Plan). The 2007 Plan authorized the grant of stock options, restricted stock, restricted stock units, stock appreciation rights and other types of equity awards to employees. We no longer grant equity under the 2007 Plan. The 2017 Plan authorizes the grant to employees of stock options, stock appreciation rights, restricted stock, restricted stock units, and other types of equity awards. A total of 2,095,049 shares have been reserved for issuance of equity awards under the 2017 Plan and may be of either Class A or Class B common stock. At December 31, 2019 , there were 1,507,489 shares available to be granted. Under the above plans, Class A and Class B options are granted at prices not less than fair market value of the underlying common stock on the date of grant. Generally, options granted have a maximum term of 10 years and vest in increments of 20% per year over a five -year period on the yearly anniversary date of the grant. Employee Stock Purchase Plans Our 2011 Employee Stock Purchase Plan (2011 ESPP) provides that eligible employees may contribute up to 10% of their compensation up to $25,000 annually toward the quarterly purchase of our Class A common stock. The employees’ purchase price is 85% of the lesser of the fair market value of the stock on the first business day or the last business day of each calendar quarter. The 2011 ESPP includes two components: a Code Section 423 Component that we intend to qualify as an “employee stock purchase plan” under Section 423 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and a Non-423 Component, which authorizes the grant of purchase rights that does not qualify as an “employee stock purchase plan” under Section 423 of the Code. We have authorized the sale of 1,300,000 shares of Class A common stock under the 2011 ESPP. Share-Based Compensation Included in our share-based compensation expense is the cost related to stock option grants, ESPP stock purchases and restricted stock unit awards. Share-based compensation expense is allocated to Cost of goods sold, Research and development expense, and Selling, general and administrative expense in the Consolidated Statements of Income. For 2019 , 2018 and 2017 , we recognized share-based compensation expense of $35.6 million , $27.8 million and $23.4 million , respectively. The income tax benefit related to share-based compensation expense was $5.6 million , $4.4 million and $5.8 million for 2019 , 2018 and 2017 , respectively. We did not capitalize any share-based compensation expense in inventory. The tax benefit from share-based compensation vested or exercised during 2019 , 2018 and 2017 was $5.4 million , $5.4 million , and $6.3 million , respectively. For options and awards, we amortize the fair value on a straight-line basis. All stock compensation awards are amortized over the requisite service periods of the awards, which are generally the vesting periods. We recognize forfeitures as they occur. Stock Options The following table summarizes stock option activity: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in millions) Outstanding, December 31, 2018 373,640 $ 138.81 Granted 34,672 $ 328.48 Exercised (55,490 ) $ 98.00 Forfeited/expired (8,300 ) $ 231.71 Outstanding, December 31, 2019 344,522 $ 162.23 4.76 $ 71.6 Unvested, December 31, 2019 94,172 $ 273.93 8.45 $ 9.1 Exercisable, December 31, 2019 250,350 $ 120.22 3.46 $ 62.5 Intrinsic value for stock options is defined as the difference between the current market value and the exercise price. The total intrinsic value on the date of exercise of stock options exercised during 2019 , 2018 and 2017 was approximately $12 million , $8 million and $10 million , respectively. Cash received from stock options exercised during 2019 , 2018 and 2017 was $2.6 million , $0.5 million and $1.6 million , respectively. As of December 31, 2019 , there was $7.0 million of total unrecognized compensation cost from stock options. This amount is expected to be recognized in the future over a weighted-average period of approximately 3 years. The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions: Year Ended December 31, 2019 2018 2017 Expected volatility 22 % 22 % 20 % Risk-free interest rate 1.69 % 2.85 % 1.87 % Expected life (in years) 7.5 7.6 7.2 Expected dividend — — — Weighted-average fair value of options granted $ 93.96 $ 105.94 $ 58.65 Volatility is based on the historical volatilities of our common stock for a period equal to the stock option’s expected life. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the number of years that we estimate, based primarily on historical experience, that the options will be outstanding prior to exercise. We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero. Restricted Stock Units Restricted stock units, which are rights to receive shares of company stock, were granted from 2009 through 2016 under the 2007 Plan and since 2017 under the 2017 Plan. The fair value of a restricted stock unit is the market value as determined by the closing price of the stock on the day of grant. The following table summarizes restricted stock unit activity: Restricted Stock Units Weighted- Average Grant-Date Fair Value Weighted-Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in millions) Outstanding, December 31, 2018 474,400 $ 235.58 Granted 174,782 $ 332.38 Vested (134,525 ) $ 206.44 Forfeited (44,715 ) $ 243.76 Outstanding, December 31, 2019 469,942 $ 279.14 2.08 $ 173.9 The total fair value of restricted stock units vested in 2019 , 2018 and 2017 was $44.8 million , $40.0 million and $27.7 million , respectively. As of December 31, 2019 , there was approximately $119.5 million of total unrecognized compensation cost related to restricted stock units. This amount is expected to be recognized over a remaining weighted-average period of approximately 3 years. Employee Stock Purchase Plans The fair value of the employees’ purchase rights under the 2011 ESPP was estimated using a Black-Scholes model with the following weighted-average assumptions: Year Ended December 31, 2019 2018 2017 Expected volatility 31 % 27 % 19 % Risk-free interest rate 2.25 % 1.82 % 0.83 % Expected life (in years) 0.24 0.24 0.24 Expected dividend — — — Weighted-average fair value of purchase rights $ 60.39 $ 55.04 $ 38.86 The major assumptions are primarily based on historical data. Volatility is based on the historical volatilities of our common stock for a period equal to the expected life of the purchase rights. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero. We sold 58,717 shares for $14.3 million , 63,464 shares for $13.6 million and 74,409 shares for $13.0 million under the 2011 ESPP to employees in 2019 , 2018 and 2017 , respectively. At December 31, 2019 , 599,531 shares remain authorized and available for issuance under the 2011 ESPP. We currently issue new shares or treasury shares, if available, to satisfy stock option exercises, restricted stock issuances and ESPP stock purchases.

10. Other Income and Expenses

10. Other Income and Expenses	12 Months Ended
	Dec. 31, 2019
Other Income and Expenses [Abstract]
Other Income and Other Expense Disclosure	10. OTHER INCOME AND EXPENSE, NET Other (income) expense, net includes the following components (in millions): Year Ended December 31, 2019 2018 2017 Interest and investment income $ (30.5 ) $ (26.6 ) $ (19.1 ) Net realized gains on investments (1.5 ) (1.6 ) (0.1 ) Other-than-temporary impairment losses on investments 5.8 0.8 7.0 Gain on sale of land — (4.1 ) — Gain on divestiture of a product line — (5.1 ) — Other expense 0.1 — 1.5 Other (income) expense, net $ (26.1 ) $ (36.6 ) $ (10.7 ) Other-than-temporary impairment losses on equity method investments were recorded in light of the investees' financial condition in the first and fourth quarters of 2019.

11. Supplemental Cash Flow Inf

11. Supplemental Cash Flow Information	12 Months Ended
	Dec. 31, 2019
Supplemental Cash Flow Information [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	11. SUPPLEMENTAL CASH FLOW INFORMATION The reconciliation of net income to net cash provided by operating activities is as follows (in millions): Year Ended December 31, 2019 2018 2017 Net income $ 1,758.7 $ 365.6 $ 122.2 Adjustments to reconcile net income to net cash provided by operating activities Depreciation and amortization 134.2 138.1 148.7 Reduction in the carrying amount of right-of-use assets 40.3 — — Share-based compensation 35.6 27.8 23.4 Gains on dispositions of securities (1.5 ) (1.6 ) (0.1 ) Other-than-temporary impairment losses on investments 5.8 0.8 7.0 Changes in fair market value of equity securities (2,031.0 ) (606.2 ) — Losses on dispositions of fixed assets 1.2 2.0 8.1 Gain on sale of land — (4.1 ) — Gain on divestiture of a product line — (5.1 ) — Payments for operating lease liabilities (38.6 ) — — Changes in fair value of contingent consideration (1.6 ) (6.2 ) (18.1 ) Decrease (increase) in accounts receivable, net 1.6 59.7 (64.1 ) Decrease (increase) in inventories, net 24.2 (12.9 ) (47.7 ) Decrease (increase) in other current assets 61.8 (15.3 ) (35.7 ) Increase (decrease) in accounts payable and other current liabilities 10.6 (45.6 ) 7.8 Decrease in income taxes payable (4.2 ) (20.9 ) (22.4 ) Increase (decrease) in deferred income taxes 450.2 120.9 (82.0 ) (Increase) decrease in other long term assets (1.7 ) 1.1 2.3 Increase (decrease) in other long term liabilities 13.4 (10.0 ) 38.1 Impairment losses on goodwill and long-lived assets — 292.5 11.5 Other (1.1 ) 4.9 5.1 Net cash provided by operating activities $ 457.9 $ 285.5 $ 104.1 Non-cash investing activities: Purchased property, plant and equipment $ 8.1 $ 5.7 $ — Purchased marketable securities and investments $ 1.4 $ 0.8 $ 2.8 Sold marketable securities and investments $ 1.3 $ — $ 0.3

12. Commitments & Contingent Li

12. Commitments & Contingent Liabilities	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingent Liabilities	12. COMMITMENTS AND CONTINGENT LIABILITIES Deferred Profit Sharing Retirement Plan We have a profit sharing plan covering substantially all U.S. employees. Contributions are made at the discretion of the Board of Directors. Bio-Rad has no liability other than for the current year’s contribution. Contribution expense was $16.1 million , $15.9 million and $16.0 million in 2019 , 2018 and 2017 , respectively. Purchase Obligations As of December 31, 2019 , we had purchase obligations that have not been recognized on our balance sheet of $35.8 million , which include agreements to purchase goods or services that are enforceable and legally binding to Bio-Rad and that specify all significant terms and exclude agreements that are cancelable without penalty. Recognition of purchase obligations occurs when products or services are delivered to Bio-Rad. The annual future fixed and determinable portion of our purchase obligations that have not been recognized on our balance sheet as of December 31, 2019 are as follows: 2020 - $34.0 million , 2021 - $1.0 million , 2022 - $0.2 million , 2023 - $0.2 million , 2024 - $0.2 million and after 2024 - $0.2 million . Long-Term Liabilities As of December 31, 2019 , we had obligations that have been recognized on our balance sheet of $118.4 million , which primarily represent recognized long-term obligations for other post-employment benefits as indicated below that are mostly due in more than 5 years, and long-term deferred revenue. Excluded are tax liabilities for uncertain tax positions and contingencies. We are not able to reasonably estimate the timing of future cash flows of these tax liabilities, therefore, our income tax obligations are excluded. The annual future fixed and determinable portion of our obligations that have been recognized on our balance sheet as of December 31, 2019 were as follows: 2020 - $5.2 million , 2021 - $12.8 million , 2022 - $4.5 million , 2023 - $4.3 million , 2024 - $3.3 million and after 2024 - $88.3 million . Letters of Credit/Guarantees In the ordinary course of business, we are at times required to post letters of credit/guarantees. The letters of credit/guarantees are issued by financial institutions to guarantee our obligations to various parties. We were contingently liable for $4.2 million of standby letters of credit/guarantees with financial institutions as of December 31, 2019 . Other Post-Employment Benefits In several foreign locations we are statutorily required to provide retirement benefits or a lump sum termination indemnity to our employees upon termination for virtually any reason. These plans are accounted for as defined benefit plans and the associated net benefit obligation at December 31, 2019 and 2018 of $81.5 million and $70.4 million , respectively, has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets. Most plans are not required to be funded, and as such, there is no trust or other device used to accumulate assets or settle these obligations. However, some of these plans require funding based on local laws in which there is a trust or other device administered by an external plan manager that is used to accumulate assets to assist in settling these obligations. The following disclosures include such plans, which are located in France, Switzerland, Germany, Korea, India, Thailand, Italy, Dubai and Japan. Obligations and Funded Status The following table sets forth the change in benefit obligations, fair value of plan assets and amounts recognized in the Consolidated Balance Sheets for the plans (in millions): Change in benefit obligation: 2019 2018 Benefit obligation at beginning of year $137.3 $136.6 Service cost 6.9 7.5 Interest cost 1.5 1.1 Plan participants' contributions 3.5 3.1 Actuarial (gain) loss 11.9 (5.4 ) Gross benefits paid (2.1 ) (3.1 ) Plan amendments 0.2 (0.5 ) Settlements (3.8 ) — Change attributable to foreign exchange (1.6 ) (2.0 ) Benefit obligation at end of year 153.8 137.3 Change in plan assets: Fair value of plan assets at beginning year 66.9 61.7 Actual return on plan assets 0.9 0.3 Employer contributions 4.7 4.0 Plan participants' contributions 3.8 3.1 Gross benefits paid (0.8 ) (1.5 ) Settlements (3.8 ) — Change attributable to foreign exchange 0.6 (0.7 ) Fair value of plan assets at end of year 72.3 66.9 Under funded status of plans $(81.5) $(70.4) Amounts recognized in the consolidated balance sheets: Current liabilities (Accrued payroll and employee benefits) $(1.1) $(1.1) Noncurrent liabilities (Other long-term liabilities) (80.4 ) (69.3 ) Net liability, end of fiscal year $(81.5) $(70.4) Components of Net Periodic Benefit Cost The following sets forth the net periodic benefit cost (income) for the periods indicated (in millions): 2019 2018 2017 Service costs $6.9 $7.5 $6.5 Interest costs 1.5 1.1 1.1 Expected returns on plan assets (1.2 ) (1.1 ) (1.1 ) Amortization of actuarial losses 1.0 1.3 1.4 Amortization of prior service costs — 0.1 — Settlements 0.9 — 1.2 Net periodic benefit costs $9.1 $8.9 $9.1 Assumptions The weighted-average assumptions used in computing the benefit obligations are as follows: 2019 2018 Discount rate 0.5 % 1.1 % Compensation rate increase 1.7 % 1.8 % The weighted-average assumptions used in computing the net periodic benefit costs are as follows: 2019 2018 2017 Discount rate 1.1 % 0.8 % 0.9 % Expected long-term rate of return on plan assets 1.8 % 1.8 % 1.9 % In some foreign locations we have service award plans that are paid based upon the number of years of employment. Under these plans, the liability at December 31, 2019 and 2018 was $3.5 million and $3.1 million , respectively, and has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets. Concentrations of Labor Subject to Collective Bargaining Agreements At December 31, 2019 , approximately seven percent of Bio-Rad's approximately 3,180

13. Legal Proceedings

13. Legal Proceedings	12 Months Ended
	Dec. 31, 2019
Legal Proceedings [Abstract]
Legal Matters and Contingencies	13. LEGAL PROCEEDINGS On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our then current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015, we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded $10.92 million , plus prejudgment interest of $141,608 , post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We previously accrued for the judgment, interest and Mr. Wadler's litigation costs. On June 6, 2017, we filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit. Oral arguments occurred on November 14, 2018. On February 26, 2019, the United States Court of Appeals for the Ninth Circuit issued its decision, reversing in part, vacating in part, and affirming in part. Specifically, the court: (1) reversed the Dodd-Frank claim, which amounts to about $2.96 million plus interest, and directed the district court to enter judgment in Bio-Rad’s favor on that claim; (2) vacated the SOX claim due to instructional error and remanded for further proceedings, including whether a new trial is needed; and (3) affirmed the California public policy claim and the $7.96 million in damages attributable to it. On March 12, 2019 we filed a petition for panel rehearing or rehearing en banc with the United States Court of Appeals for the Ninth Circuit, and this petition was denied on April 8, 2019. On September 24, 2019, Mr. Wadler filed a dismissal with prejudice of all remaining claims under the lawsuit with the U.S. District Court, Northern District of California as a result of a Confidential Settlement Agreement and Satisfaction of Judgment that the parties entered into that was last executed on September 6, 2019. This matter did not have a material impact on our 2019 results of operations and is now closed. We are also party to various other claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.

14. Segment Reporting

14. Segment Reporting	12 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Segment Information	14. SEGMENT INFORMATION Bio-Rad is a multinational manufacturer and worldwide distributor of its own life science research products and clinical diagnostics products. We have two reportable segments: Life Science and Clinical Diagnostics. These reportable segments are strategic business lines that offer more than 9,000 different products and services and require different marketing strategies. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve. The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. These products are sold to university and medical school laboratories, pharmaceutical and biotechnology companies, food testing laboratories and government and industrial research facilities. The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. These products are sold to reference laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories, transfusion laboratories and insurance and forensic testing laboratories. Other Operations include the remainder of our Analytical Instruments segment. Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. The accounting policies of the segments are the same as those described in Significant Accounting Policies (see Note 1). Segment profit or loss includes an allocation of corporate expense based upon sales and an allocation of interest expense based upon accounts receivable and inventories. The difference between total segment allocated interest expense, depreciation and amortization, and capital expenditures and the corresponding consolidated amounts is attributable to our corporate headquarters. Segments are expected to manage only assets completely under their control. Accordingly, segment assets include primarily accounts receivable, inventories and gross machinery and equipment. Goodwill balances have been included in corporate for segment reporting purposes. Information regarding industry segments at December 31, 2019 , 2018 , and 2017 and for the years then ended is as follows (in millions): Life Science Clinical Diagnostics Other Operations Segment net sales 2019 $ 885.9 $ 1,412.0 $ 13.8 2018 861.7 1,411.8 15.9 2017 785.2 1,360.8 14.2 Allocated interest expense 2019 $ 7.4 $ 15.9 $ 0.1 2018 7.2 16.7 0.1 2017 7.0 14.9 — Depreciation and amortization 2019 $ 29.4 $ 71.7 $ 0.9 2018 34.1 72.0 0.5 2017 36.2 80.2 — Segment profit (loss) 2019 $ 72.1 $ 148.5 $ (1.5 ) 2018 28.7 (145.7 ) 0.2 2017 (9.9 ) 114.8 1.4 Segment assets 2019 $ 496.1 $ 1,075.8 $ 9.2 2018 450.2 949.0 5.9 Capital expenditures 2019 $ 16.6 $ 58.9 $ 0.6 2018 36.7 60.5 0.5 Clinical Diagnostics segment loss for 2018 was due to impairment losses taken on goodwill of $276.1 million (see Note 4 to the consolidated financial statements). Segment assets at December 31, 2019 increased from December 31, 2018 balances due to inclusion of operating lease right-of-use assets in segment assets (see Note 16 to the consolidated financial statements). Net corporate operating expense consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker. The following reconciles total segment profit to consolidated income before taxes (in millions): Year Ended December 31, 2019 2018 2017 Total segment profit (loss) $ 219.1 $ (116.8 ) $ 106.3 Foreign currency exchange losses, net (2.2 ) (2.9 ) (9.1 ) Net corporate operating, interest and other expense not allocated to segments (12.9 ) (10.4 ) (10.1 ) Change in fair market value of equity securities 2,031.0 606.2 — Other income (expense), net 26.1 36.6 10.7 Consolidated income before income taxes $ 2,261.1 $ 512.7 $ 97.8 The following reconciles total segment assets to consolidated total assets (in millions): December 31, 2019 2018 Total segment assets $ 1,581.1 $ 1,405.1 Cash and other current assets 1,233.5 1,047.2 Property, plant and equipment, net, and operating lease right-of-use assets, excluding segment specific balances 66.8 79.9 Goodwill, net 264.1 219.8 Other long-term assets 4,863.4 2,859.1 Total assets $ 8,008.9 $ 5,611.1 Other long-term assets at December 31, 2019 increased from December 31, 2018 balance due to increase in fair market value of equity securities (see Note 3 to the consolidated financial statements). The following presents net sales to external customers by geographic region based primarily on the location of the use of the product or service (in millions): Year Ended December 31, 2019 2018 2017 Europe $ 770.3 $ 792.0 $ 758.5 Asia 505.0 495.5 461.3 United States 899.1 863.6 800.2 Other (primarily Canada and Latin America) 137.3 138.3 140.0 Total net sales $ 2,311.7 $ 2,289.4 $ 2,160.2 The following presents Property, plant and equipment, net, Operating lease right-of-use assets and Other assets, excluding deferred income taxes, by geographic region based upon the location of the asset (in millions): December 31, 2019 2018 Europe $ 198.3 $ 129.1 Asia 51.5 20.7 United States 468.7 369.2 Other (primarily Canada and Latin America) 12.7 11.1 Total Property, plant and equipment, net, Operating lease right-of-use assets and Other assets, excluding deferred income taxes $ 731.2 $ 530.1 Prior year amounts have been adjusted to exclude Other investments.

15. Restructuring Costs (Notes)

15. Restructuring Costs (Notes)	12 Months Ended
	Dec. 31, 2019
Restructuring Costs [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	RESTRUCTURING COSTS Restructuring Costs for European Reorganization In May 2016, we announced that we would take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with creation and evolution of our organization structure and coordinated with the implementation of our global single instance enterprise resource planning ("ERP") platform, were incurred through and completed in December 2019. We recorded approximately $(0.1) million , $(0.2) million and $0.5 million in restructuring charges and adjustments related to severance and other employee benefits for the years ended December 31, 2019 , 2018 and 2017 , respectively. From May 2016 to December 31, 2019 , total expenses were $12.7 million . The amounts recorded were reflected in Cost of goods sold of $(0.1) million , $(0.1) million and $(0.2) million , and in Selling, general and administrative expense of zero, $(0.1) million and $0.7 million in the Consolidated Statements of Income for the years ended December 31, 2019 , 2018 and 2017 , respectively. The amounts adjusted were primarily for additional positions identified for elimination, partially offset by employees finding other positions within Bio-Rad or leaving prematurely. The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions): 2019 2018 Life Science Clinical Diagnostics Total Life Science Clinical Diagnostics Total Balance as of January 1 $ 0.6 $ 1.0 $ 1.6 $ 2.2 $ 4.1 $ 6.3 Adjustment to expense — (0.1 ) (0.1 ) (0.1 ) (0.1 ) (0.2 ) Cash payments (0.3 ) (0.5 ) (0.8 ) (1.5 ) (2.9 ) (4.4 ) Reserve transferred to European and North American Reorganization restructuring costs reserve (see below) (0.3 ) (0.4 ) (0.7 ) — — — Foreign currency translation gains — — — — (0.1 ) (0.1 ) Balance as of December 31 $ — $ — $ — $ 0.6 $ 1.0 $ 1.6 Restructuring Costs for Termination of a Diagnostics Research and Development Project and Facility Closures In December 2017, we announced the termination of a diagnostics research and development project in Europe. We recorded restructuring charges and adjustments related to severance and employee benefits of less than $(0.1) million , $0.4 million and $11.0 million and asset write-offs and exit costs of zero, $(0.1) million and $10.1 million for the years ended December 31, 2019 , 2018 and 2017 , respectively. From December 2017 to December 31, 2019 , total expenses were $21.4 million . This restructuring plan was completed in December 2019. In June 2018, we announced the closure of a small manufacturing operation in Munich, Germany. We recorded restructuring charges and adjustments related to severance and employee benefits of $(0.3) million and $1.7 million for the years ended December 31, 2019 and 2018 , respectively. From June 2018 to December 31, 2019 , total expenses were $1.4 million . This restructuring plan was completed in November 2019. In December 2018, we announced the closure of a small manufacturing facility outside Paris, France. We recorded restructuring charges and adjustments related to severance and employee benefits of $(0.1) million and $3.9 million and exit costs of zero and $0.2 million for the years ended December 31, 2019 and 2018 , respectively. From December 2018 to December 31, 2019 , total expenses were $4.0 million . Restructuring charges for the termination of a diagnostics research and development project and the facility closures are all included in our Clinical Diagnostics segment's results of operations. The amounts recorded were reflected in Cost of goods sold of $(0.3) million , $5.4 million and $2.3 million , in Selling, general and administrative expense of zero, $0.4 million and $3.3 million , and in Research and development expense of $(0.1) million , $0.3 million and $15.5 million in the Consolidated Statements of Income for the years ended December 31, 2019 , 2018 and 2017 , respectively. The liability of $3.2 million as of December 31, 2019 consisted of $1.8 million recorded in Accrued payroll and employee benefits, $0.2 million recorded in Other current liabilities, and $1.2 million recorded in Other long-term liabilities in the Consolidated Balance Sheets. The following table summarizes the activity for the termination of the diagnostics research and development project and the facility closures restructuring reserves for severance and exit costs (in millions): 2019 2018 Balance as of January 1 $ 11.5 $ 14.1 Charged to expense — 5.8 Adjustment to expense (0.4 ) 0.3 Cash payments (7.7 ) (8.4 ) Foreign currency translation gains (0.2 ) (0.3 ) Balance as of December 31 $ 3.2 $ 11.5 Restructuring Costs for European and North American Reorganization In November 2019, we announced our strategy-driven restructuring plan. We expect that a significant portion of the net savings resulting from this restructuring plan will be repurposed in alignment with our portfolio strategy. The restructuring plan includes a workforce reduction in Europe, the United States and Canada, and is expected to be incurred through 2020. We recorded $25.3 million of expense in restructuring charges related to severance and employee benefits for the year ended December 31, 2019. The liability of $25.3 million as of December 31, 2019 was recorded in Accrued payroll and employee benefits in the Consolidated Balance Sheets. The amounts recorded were reflected in Cost of goods sold of $4.8 million , in Selling, general and administrative expense of $14.4 million and in Research and development expense of $6.1 million in the Consolidated Statements of Income for the year ended December 31, 2019 . The following table summarizes the activity of our European and North American reorganization restructuring reserves for severance (in millions): 2019 Life Science Clinical Diagnostics Total Balance as of January 1 $ — $ — $ — Charged to expense 6.2 19.1 25.3 Cash payments (0.4 ) (0.7 ) (1.1 ) Reserve transferred from European Reorganization restructuring costs reserve (see above) 0.3 0.4 0.7 Foreign currency translation losses 0.1 0.3 0.4 Balance as of December 31 $ 6.2 $ 19.1 $ 25.3

16. Leases (Notes)

16. Leases (Notes)	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Leases of Lessee Disclosure [Text Block]	16. LEASES We have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. Our leases have remaining lease terms of 1 year to 19 years, which includes our determination to exercise renewal options. The components of lease expense were as follows (in millions): Twelve Months Ended December 31, 2019 Operating lease cost $ 51.4 Finance lease cost: Amortization of right-to-use assets $ 0.6 Interest on lease liabilities 0.9 Total finance lease cost $ 1.5 Sublease income $ 3.0 The sublease is for a building with a term that ends in 2025, with no options to extend or renew. Operating lease cost includes original reduction in the carrying amount of right-of-use assets, the impact of remeasurements, modifications, impairments and abandonments. Historically, our short-term leases, reflecting leases with a lease term of one year or less, are predominantly comprised of leases with a lease term of one month or less, which are not significant. Operating lease variable cost is primarily comprised of reimbursed actual common area maintenance, property taxes and insurance, which are immaterial. Supplemental cash flow information related to leases was as follows (in millions): Twelve Months Ended December 31, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 47.2 Operating cash flows from finance leases $ 0.9 Financing cash flows from finance leases $ 0.6 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 28.7 Finance leases $ 0.2 Supplemental balance sheet information related to leases was as follows (in millions): December 31, 2019 Operating Leases Operating lease right-of-use assets $ 201.9 Current operating lease liabilities $ 35.4 Operating lease liabilities 176.0 Total operating lease liabilities $ 211.4 December 31, 2019 Finance Leases Property, plant and equipment, gross $ 11.4 Less: accumulated depreciation and amortization (4.2 ) Property, plant and equipment, net $ 7.2 Current maturities of long-term debt and notes payable $ 0.5 Long-term debt, net of current maturities 11.2 Total finance lease liabilities $ 11.7 December 31, 2019 Weighted Average Remaining Lease Term Operating leases - in years 9 Finance leases - in years 18 Weighted Average Discount Rate Operating leases 4.2 % Finance leases 6.5 % Maturities of lease liabilities were as follows (in millions): Year Ending December 31, Operating Leases Finance Leases 2020 $ 41.0 $ 1.1 2021 35.8 1.3 2022 28.6 1.2 2023 24.5 1.1 2024 21.8 1.1 Thereafter 103.7 15.2 Total lease payments 255.4 21.0 Less imputed interest (44.0 ) (9.3 ) Total $ 211.4 $ 11.7 The value of our operating lease portfolio is principally for facilities with longer durations than the lesser value vehicles and other equipment with shorter terms and higher-turn over. As of December 31, 2019 , we have an additional lease for a facility in Texas that has not commenced of $1.6 million . The operating lease will commence in either the second or third quarter of 2020 with a lease term of four years . Operating and Capital Lease Commitments Under ASC 840, Leases Rents and Leases Rental expense under operating leases was $47.4 million and $43.6 million in 2018 and 2017, respectively. Leases were principally for facilities and automobiles. Annual future minimum lease payments at December 31, 2018 under operating leases were as follows: 2019 - $44.4 million ; 2020 - $37.8 million ; 2021 - $27.4 million ; 2022 - $19.7 million ; 2023 - $13.9 million ; and 2024 and beyond - $25.6 million . The total minimum rentals to be received in the future for the sublease as of December 31, 2018 were $17.8 million and ends in 2025. Maturities of our capital lease obligations at December 31, 2018 were as follows: 2019 - $0.5 million ; 2020 - $0.2 million ; 2021 - $0.5 million ; 2022 - $0.4 million ; 2023 - $0.4 million ; and thereafter - $9.9 million .

17. Quarterly Financial Data

17. Quarterly Financial Data	12 Months Ended
	Dec. 31, 2019
Quarterly Financial Data [Abstract]
Quarterly Financial Data [Text Block]	17. QUARTERLY FINANCIAL DATA (UNAUDITED) Summarized quarterly financial data for 2019 and 2018 are as follows (in millions, except per share data): First Quarter Second Quarter Third Quarter Fourth Quarter 2019 Net sales $ 554.0 $ 572.6 $ 560.6 $ 624.5 Gross profit 311.8 307.8 307.0 330.4 Net income (loss) 865.2 598.8 (258.8 ) 553.5 Basic earnings (loss) per share $ 29.03 $ 20.08 $ (8.68 ) $ 18.50 Diluted earnings (loss) per share $ 28.74 $ 19.86 $ (8.68 ) $ 18.31 2018 Net sales $ 551.5 $ 575.9 $ 545.1 $ 616.9 Gross profit 302.2 301.7 286.7 332.6 Net income (loss) 656.8 268.0 269.3 (828.5 ) Basic earnings (loss) per share $ 22.05 $ 8.99 $ 9.02 $ (27.73 ) Diluted earnings (loss) per share $ 21.77 $ 8.87 $ 8.89 $ (27.73 ) As a result of the net losses for the three months ended September 30, 2019 and December 31, 2018, all potentially issuable common shares have been excluded from the diluted shares used in the computation of earnings per share as their effects were anti-dilutive. Financial data for the fourth quarter of 2019 were negatively affected by the December 2019 Cyberattack, and restructuring costs for the European and North American reorganization, and are described in Item 7 and Note 15 to the consolidated financial statements, respectively. These negative effects were offset by a $646.0 million increase in fair market value of equity securities. The net losses for the three months ended September 30, 2019 and December 31, 2018 were primarily due to a $390.6 million and $814.1 million decrease in fair market value of equity securities, respectively. These changes in fair market value of equity securities mostly consisted of holding gains or losses on our investment in Sartorius AG. The net loss for the three months ended December 31, 2018 also included impairment losses on goodwill and long-lived assets in the amount of $292.5 million

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accoutns	12 Months Ended
	Dec. 31, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	BIO-RAD LABORATORIES, INC. SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS Years Ended December 31, 2019 , 2018 , and 2017 (in thousands) Allowance for doubtful accounts receivable Balance at Beginning of Year (Credited) Charged to Costs and Expenses Deductions Balance at End of Year 2019 $ 26,713 $ (1,240 ) $ (5,268 ) $ 20,205 2018 $ 25,549 $ 11,527 $ (10,363 ) $ 26,713 2017 $ 23,367 $ 11,174 $ (8,992 ) $ 25,549 Valuation allowance for long-term deferred tax assets Balance at Beginning of Year Charged (Credited) to Income Tax Expense Deductions Balance at End of Year 2019 $ 70,769 $ — $ (3,579 ) $ 67,190 2018 $ 66,356 $ 4,413 $ — $ 70,769 2017 $ 66,403 $ (47 ) $ — $ 66,356

1. Significant Accounting Pol_2

1. Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of intercompany balances and transactions. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued. The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading. To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects for those events and conditions.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less which are readily convertible into cash. Cash equivalents are stated at cost, which approximates fair value.
Short-term Restricted Investments	Short-term Restricted Investments Short-term restricted investments of $5.6 million at both December 31, 2019 and 2018 represent a money market fund that is renewed annually for collateral that secures worker's compensation and general liability insurance. Investment income accrues to Bio-Rad and is recorded in Cash and cash equivalents in the Consolidated Balance Sheets.
Available-for-sale Investments	Available-for-Sale Investments Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities, U.S. government sponsored agencies and marketable equity securities. Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date. Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations. Available-for-sale investments are reported at fair value based on quoted market prices and other observable market data. Unrealized gains and losses are reported as a component of other comprehensive income, net of any related tax effect. Effective January 1, 2018, changes in fair value for equity securities are reported in Change in fair market value of equity securities in the Consolidated Statements of Income due to the adoption of ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Unrealized losses are charged against income when a decline in the fair value of an individual security is determined to be other-than-temporary. We review our available-for-sale debt securities for other-than-temporary losses on a quarterly basis. Realized gains and losses and other-than-temporary impairments on investments are included in Other (income) expense, net (see Note 10).
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, investments, foreign exchange contracts and trade accounts receivable. Cash and cash equivalents and investments are placed with various highly rated major financial institutions located in different geographic regions. The forward contracts used in managing our foreign currency exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements. We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated domestic and international financial institutions. In the event of non-performance by these counterparties, the carrying values of our financial instruments represent the maximum amount of loss we would have incurred as of our fiscal year-end. We perform credit evaluation procedures related to our trade receivables and with the exception of certain developing countries, generally do not require collateral. As a result of increased risk in certain developing countries, some Bio-Rad sales are subject to collateral letters of credit from our customers. Credit risk for trade accounts receivable is generally limited due to the large number of customers and their dispersion across many geographic areas. However, a significant amount of trade receivables are with national healthcare systems in countries within the European Union.
Accounts Receivable	Accounts Receivable We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. The amount of the allowance is determined by analyzing known uncollectible accounts, aged receivables, economic conditions in the customers’ country or industry, historical losses and our customers’ credit-worthiness. Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance.
Inventory	Inventory Inventories are valued at the lower of cost and net realizable value and include material, labor and overhead costs. The first-in, first-out method is used to relieve inventory for products sold.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are carried at cost, less accumulated depreciation and amortization. Included in property, plant and equipment are buildings and equipment acquired under capital lease arrangements, reagent rental equipment and capitalized software, including costs for software developed or obtained for internal use. Property, plant and equipment are assessed for impairment quarterly or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets. The estimated useful lives of property, plant and equipment are generally as follows: buildings and leasehold improvements, 10 - 39 years or the term of the leases or life of the improvements, whichever is shorter; reagent rental equipment, 1 - 5 years; and equipment, 3 - 12 years.
Leases	Leases We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use (“ROU”) assets, Current operating lease liabilities, and Operating lease liabilities in our Consolidated Balance Sheet as of December 31, 2019 . Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities in our Consolidated Balance Sheet as of December 31, 2019 .
Lessor, Leases	Where we act as lessor in our reagent rental arrangements, we allocate the consideration in the contract to the separate lease components and non-lease components. After allocation, the amount of variable payments allocated to lease components will be recognized as income under the lease accounting standard ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Such reagent rental arrangements are more fully described below under the caption "Reagent Rental Agreements."
Goodwill	Goodwill Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of acquired businesses. Goodwill is assessed for impairment by applying fair value based tests annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We perform impairment tests of goodwill at our reporting unit level, which is one level below our operating segments. Our reporting units are identified as components for which discrete financial information is available and is regularly reviewed by management. Goodwill amounts are assigned to reporting units at the time of acquisition. The goodwill impairment amount will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. We use a projected discounted cash flow model to determine the fair value of a reporting unit.
Long-Lived Assets	Long-Lived Assets For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. We assess the impairment of long-lived assets (including identifiable intangible assets and operating lease right-of-use assets) quarterly or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors that we consider important that could trigger an impairment review include: • significant under-performance relative to expected, historical or projected future operating results; • significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our overall business; • a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of at a loss before the end of its previously estimated useful life; and • significant negative industry, legal, regulatory or economic trends. When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method. Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets. We estimate the future cash flows of the long-lived assets using current and long-term financial forecasts. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If this is the case, an impairment loss would be recognized. The impairment loss recognized is the amount by which the carrying amount exceeds the fair value.
Income Taxes	Income Taxes We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities reflect the tax effects of net operating losses, tax credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. They are determined using enacted tax rates in effect for the year in which such temporary differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. We record deferred tax assets to the extent we believe these assets will more likely than not be realized. In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. When we establish, or reduce the valuation allowance against our deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period that determination to change the valuation allowance is made. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than a 50% likelihood of being realized upon settlement. The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in the provision for income taxes. On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The Tax Act made broad and complex changes to the U.S. tax code, including the imposition of a one-time mandatory deemed repatriation tax (“Transition Tax”) on certain earnings accumulated offshore since 1986 and the reduction of the corporate tax rate from 35% to 21% for U.S. taxable income, resulting in a one-time remeasurement of U.S. federal deferred tax assets and liabilities. In 2017, we recorded an income tax benefit of $70 million related to the Transition Tax and remeasurement of our U.S. federal deferred tax assets and liabilities. We completed our accounting for the Tax Act under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) in 2018, which resulted in an additional income tax benefit of $49 million .
Revenue Recognition	Revenue Recognition On January 1, 2018, we adopted Accounting Standards Codification ("ASC") 606, "Revenue from Contracts with Customers," using the modified retrospective method applied to those contracts that were not completed as of January 1, 2018. We recorded a net reduction to opening retained earnings of $0.1 million as of January 1, 2018 due to the cumulative impact of adopting ASC 606 with the impact primarily related to a customer loyalty program in the United States for which the resulting non-cash consideration is treated as variable consideration under the new revenue recognition accounting standard. We recognize revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment, and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service. At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, transaction prices are allocated to performance obligations based on stand-alone selling prices. The method used to determine the stand-alone selling prices for service revenues is based on the observable prices when the services have been sold separately. In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance. We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.
Revenue Recognition, Leases	Reagent Rental Agreements Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at lease commencement. Where we have determined that such an arrangement contains a lease, we next must ascertain its lease classification for purposes of applying appropriate accounting treatment as an operating, sales-type or direct financing lease. In addition, for purposes of determining the lease term used in performing the lease classification test, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if the customer is reasonably certain to exercise that option, the periods covered by an option to terminate the lease if the customer is reasonably certain not to exercise that option, and the periods covered by the option to extend (or not to terminate) the lease in which exercise of the option is controlled by the company. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel, the period in which the contract is enforceable is a very short period and therefore the lease term has been limited to the noncancellable period. Furthermore, it has historically been very rare for these arrangements to contain an option for the lessee to purchase the underlying asset. As discussed further above under the caption “Leases” and below under the caption “Recent Accounting Pronouncements Adopted,” as well as in Note 16, Leases, we adopted ASC 842, “Leases,” on a modified retrospective basis effective January 1, 2019 with practical expedients, and did not restate comparative prior periods. We concluded that the use of the instrument (referred to as “lease elements”) is not within the guidance of ASC 606 but rather ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After allocation, the amount of variable payments allocated to lease components will be recognized as income under ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Upon our adoption of ASC 842 in 2019, the maintenance services, along with the reagents, are now allocated to the non-lease elements and will be recognized as income in accordance with ASC 606. This change is in alignment with the requirements of ASC 842, and has resulted in a decrease in the amount of rental income and a corresponding increase in the amount of maintenance service revenue that is included in total reported Net sales in our consolidated income statements. Generally, the terms of the arrangements result in the transfer of control on reagents upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer. Historically, our reagent rental arrangements have been predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as very few of such arrangements contain any fixed/minimum lease payments. As a result, our lease income is heavily variable in nature. Further, our reagent rental arrangements are predominantly classified as operating leases, and any sales-type leases represent in aggregate a very insignificant amount of lease income. Hence, our reported lease income is primarily variable in nature and is recognized as the reagents are consumed by the customer or delivered. Revenue allocated to the lease elements of these reagent rental arrangements represents approximately 3% and 5% of total revenue for 2019 and 2018 , respectively, and is included as part of the Net sales in our Consolidated Statements of Income. Contract costs: As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities. Disaggregation of Revenue: The disaggregation of our revenue by geographic region based primarily on the location of the use of the product service, and by industry segment sources, and the disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 14).
Revenue Recognition, Deferred Revenue	Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are generally recognized ratably over the term of the service contract as our performance extends over the life of the arrangement. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The increase in our total deferred revenue balance from $37.3 million at December 31, 2018 to $45.8 million at December 31, 2019 was primarily driven by $33.1 million , net, of cash payments received or due in advance of satisfying our performance obligations, partially offset by $24.6 million of revenue recognized that were included in our deferred revenue balance as of December 31, 2018
Warranty	We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback. A review is performed on a quarterly basis to assess the adequacy of our warranty accrual. Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Consolidated Balance Sheets, were as follows (in millions): 2019 2018 January 1 $ 10.1 $ 18.7 Provision for warranty 9.9 25.5 Actual warranty costs (11.0 ) (34.1 ) December 31 $ 9.0 $ 10.1
Shipping and Handling	Shipping and Handling We classify all freight costs billed to customers as Net sales. Related freight costs are recognized upon transfer of control of the promised products to customers as a fulfillment cost and included in Cost of goods sold.
Research and Development Expense	Research and Development Internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed. We conduct extensive research and development activities in all areas of our business, employing approximately 780 employees worldwide in these activities, including degreed scientists and technical support staff. Research and development has played a major role in Bio-Rad’s growth and is expected to continue to do so in the future. Our research teams are continuously developing new products and new applications for existing products. In our development of new products and applications, we interact with scientific and medical professionals at universities, hospitals and medical schools, and within our industry.
Foreign Currency	Foreign Currency Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period. Income statement items are translated at average exchange rates for the period. The resulting translation adjustments are recorded as a separate component of stockholders’ equity. Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the Consolidated Statements of Income. Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction.
Forward Foreign Exchange Contracts	Forward Foreign Exchange Contracts As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded as an asset or liability measured at their fair value at each balance sheet date. The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all of which are recorded in Foreign exchange losses, net in the Consolidated Statements of Income.
Share-based Compensation Plans	Share-Based Compensation Plans Share-based compensation expense for all share-based payment awards granted is determined based on the grant-date fair value. We recognize these compensation costs over the requisite service period of the award, which is generally the vesting term of the share-based payment awards. Forfeitures are recognized as they occur. These plans are described more fully in Note 9.
Earnings Per Share	Earnings Per Share Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period. Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding. Potential common shares are excluded from the diluted earnings per share calculation if the effect would be anti-dilutive. The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands): Year Ended December 31, 2019 2018 2017 Basic weighted average shares outstanding 29,843 29,836 29,655 Effect of potentially dilutive stock options and restricted stock awards 341 392 379 Diluted weighted average common shares 30,184 30,228 30,034 Anti-dilutive stock options and restricted stock awards excluded from the computation of diluted EPS 98 84 13
Fair Value of Financial Instruments	Fair Value of Financial Instruments For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts approximate fair value. The estimated fair value of financial instruments is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) using available market information or other appropriate valuation methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value. The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value (see Note 3).
New Accounting Pronouncements	Recent Accounting Pronouncements Adopted In August 2018, the FASB issued ASU 2018-15, "Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract." ASU 2018-15 amends the definition of a hosting arrangement and requires a customer in a hosting arrangement that is a service contract to capitalize certain implementation costs as if the arrangement was an internal-use software project. The internal-use software guidance states that only qualifying costs incurred during the application development stage can be capitalized. We prospectively adopted ASU 2018-15 effective January 1, 2019. As of December 31, 2019 , we capitalized $3.1 million of implementation costs for cloud computing arrangements, net of accumulated amortization, primarily for business analytics software. These costs were recorded in Other current assets and Other assets in the Consolidated Balance Sheet. In August 2018, the SEC issued Final Rule Release No. 33-10532, "Disclosure Update and Simplification" that extends to interim periods the annual disclosure requirement of presenting the changes in stockholders' equity, which was effective in the first quarter of 2019. In February 2016, the FASB issued ASU 2016-02, "Leases," and related accounting standard updates, which requires, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures are enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. We adopted ASU 2016-02 on a modified retrospective basis effective January 1, 2019 with practical expedients, and did not restate comparative prior periods. The practical expedients elected in transition included, among other items, for leases that existed prior to January 1, 2019, not reassessing whether any contracts are or contain embedded leases, not reassessing the classification of existing leases, and not reassessing whether previously capitalized initial direct costs qualify for capitalization. Where we act as a lessee, the adoption of the standard resulted in material additions to the balance sheet for right-of-use assets and the associated liabilities. See Note 16, Leases. Where we act as a lessee, we also elected not to separate lease and non-lease components. Where we act as a lessor in reagent rental arrangements, there was an insignificant impact to our Consolidated Financial Statements, which is more fully described above under the caption "Reagent Rental Agreements." Recent Accounting Pronouncements to be Adopted In January 2020, the FASB issued ASU 2020-01, Clarifying the Interactions between Topic 321 Investments—Equity Securities, Topic 323 Investments—Equity Method and Joint Ventures, and Topic 815 Derivatives and Hedging. ASU 2020-01 clarifies that a company should consider observable transactions that require a company to either apply or discontinue the equity method of accounting under Topic 323 for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method. ASU 2020-01 also clarifies that, when determining the accounting for certain forward contracts and purchased options a company should not consider, whether upon settlement or exercise, if the underlying securities would be accounted for under the equity method or fair value option. ASU 2020-01 is effective January 1, 2021 and early adoption is permitted at the beginning of any interim period on a prospective basis. We are currently evaluating the effect of ASU 2020-01 and the consideration of early adoption. In December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes," which eliminates certain exceptions within ASC 740, Income Taxes , and clarifies other aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020 and early adoption is permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. We are currently evaluating the effect of adopting this pronouncement on our financial statements and disclosures. In November 2018, the FASB issued ASU 2018-18, "Clarifying the Interaction between Topic 808 and Topic 606." Topic 808 is Collaborative Arrangements, and Topic 606 is Revenue from Contracts with Customers. ASU 2018-18 clarifies that certain transactions between collaborative partners should be accounted for as revenue under ASC 606 when the collaborative partner is a customer. We currently do not have any customers that are collaborative partners or anticipate any in the near future. ASU 2018-18 will be effective January 1, 2020. In August 2018, the FASB issued ASU 2018-14, "Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans." ASU 2018-14 eliminates and adds certain disclosures for defined benefit plans. ASU 2018-14 is effective for fiscal years ending after December 15, 2020 using a retrospective approach. We are currently evaluating the disclosures but do not expect ASU 2018-14 to have a material impact to our disclosures for defined benefit plans. In August 2018, the FASB issued ASU 2018-13, "Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement." ASU 2018-13 eliminates, adds and modifies certain disclosures for fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. We do not expect ASU 2018-13 to have a material impact to our fair value disclosures.

1. Significant Accounting Pol_3

1. Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Schedule of Product Warranty Liability	Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Consolidated Balance Sheets, were as follows (in millions): 2019 2018 January 1 $ 10.1 $ 18.7 Provision for warranty 9.9 25.5 Actual warranty costs (11.0 ) (34.1 ) December 31 $ 9.0 $ 10.1
Schedule of Weighted Average Number of Shares	The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands): Year Ended December 31, 2019 2018 2017 Basic weighted average shares outstanding 29,843 29,836 29,655 Effect of potentially dilutive stock options and restricted stock awards 341 392 379 Diluted weighted average common shares 30,184 30,228 30,034 Anti-dilutive stock options and restricted stock awards excluded from the computation of diluted EPS 98 84 13

3. Fair Value Measurements (Tab

3. Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Debt Securities, Available-for-sale [Table Text Block]	Available-for-sale investments consist of the following (in millions): December 31, 2019 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Short-term investments: Corporate debt securities $ 203.2 $ 1.4 $ (0.1 ) $ 204.5 Municipal obligations 11.5 0.1 — 11.6 Asset-backed securities 72.7 0.2 (0.1 ) 72.8 U.S. government sponsored agencies 105.6 0.7 (0.2 ) 106.1 Foreign government obligations 4.7 — — 4.7 Other foreign obligations 3.1 — — 3.1 400.8 2.4 (0.4 ) 402.8 Long-term investments: Asset-backed securities 0.1 — — 0.1 0.1 — — 0.1 Total $ 400.9 $ 2.4 $ (0.4 ) $ 402.9
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a reconciliation of the Level 3 contingent consideration liabilities measured at estimated fair value (in millions): December 31, 2018 $ 8.4 Analytical flow cytometer platform: Payment of sales milestone (2.5 ) Net decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense (1.6 ) Foreign distributor earn-outs: Acquisition of foreign distributor $ 0.6 December 31, 2019 $ 4.9
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	The following table provides q ua ntitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of December 31, 2019 . Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement. Valuation Technique Unobservable Input Percentage Analytical flow cytometer platform Probability-weighted income approach Sales milestones: Discount rate 11.1 % Cost of debt 3.9 %
Schedule of Derivative Instruments [Table Text Block]	The following is a summary of our forward foreign currency exchange contracts (in millions): December 31, 2019 Contracts maturing in January through March 2020 to sell foreign currency: Notional value $ 52.0 Unrealized gain $ 0.3 Contracts maturing in January through March 2020 to purchase foreign currency: Notional value $ 269.1 Unrealized loss $ (0.3 )
Financial assets and liabilities carried at fair value on a recurring basis	Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2019 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 42.9 $ — $ 42.9 Time deposits 31.2 10.0 — 41.2 Asset-backed securities — 0.1 — 0.1 Money market funds 69.9 — — 69.9 Total cash equivalents (a) 101.1 53.0 — 154.1 Restricted investment 5.6 — — 5.6 Equity Securities (b) 4,664.4 — — 4,664.4 Available-for-sale investments: Corporate debt securities — 204.5 — 204.5 U.S. government sponsored agencies — 106.1 — 106.1 Foreign government obligations — 4.7 — 4.7 Other foreign obligations — 3.1 — 3.1 Municipal obligations — 11.6 — 11.6 Asset-backed securities — 72.9 — 72.9 Total available-for-sale investments (c) — 402.9 — 402.9 Forward foreign exchange contracts (d) — 0.9 — 0.9 Total financial assets carried at fair value $ 4,771.1 $ 456.8 $ — $ 5,227.9 Financial liabilities carried at fair value: Forward foreign exchange contracts (e) $ — $ 1.0 $ — $ 1.0 Contingent consideration (f) — — 4.9 4.9 Total financial liabilities carried at fair value $ — $ 1.0 $ 4.9 $ 5.9 Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2018 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 77.8 $ — $ 77.8 Time deposits 22.7 10.0 — 32.7 Asset-backed securities — 0.3 — 0.3 Money market funds 36.9 — — 36.9 Total cash equivalents (a) 59.6 88.1 — 147.7 Restricted investment: 5.6 — — 5.6 Equity securities (b) 2,672.9 — — 2,672.9 Available-for-sale investments: Corporate debt securities — 215.0 — 215.0 U.S. government sponsored agencies — 80.3 — 80.3 Foreign government obligations — 3.6 — 3.6 Municipal obligations — 11.0 — 11.0 Asset-backed securities — 63.3 — 63.3 Total available-for-sale investments (c) — 373.2 — 373.2 Forward foreign exchange contracts (d) — 0.6 — 0.6 Total financial assets carried at fair value $ 2,738.1 $ 461.9 $ — $ 3,200.0 Financial liabilities carried at fair value: Forward foreign exchange contracts (e) $ — $ 0.7 $ — $ 0.7 Contingent consideration (f) — — 8.4 8.4 Total financial liabilities carried at fair value $ — $ 0.7 $ 8.4 $ 9.1 (a) Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets. (b) Equity securities are included in the following accounts in the Consolidated Balance Sheets (in millions): December 31, 2019 December 31, 2018 Short-term investments $ 51.0 $ 40.2 Other investments 4,613.4 2,632.7 Total $ 4,664.4 $ 2,672.9 The year-to-date unrealized gains on our equity securities still held as of December 31, 2019 were $2,031.1 million and were primarily due to our investment in Sartorius AG and are recorded in our Consolidated Statements of Income. (c) Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions): December 31, December 31, 2018 Short-term investments $ 402.8 $ 373.0 Other investments 0.1 0.2 Total $ 402.9 $ 373.2 (d) Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets. (e) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets. (f) Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions): December 31, 2019 December 31, 2018 Other current liabilities $ 3.3 $ 3.2 Other long-term liabilities 1.6 5.2 Total $ 4.9 $ 8.4
Schedule of available-for-sale investments	Available-for-sale investments consist of the following (in millions): December 31, 2018 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Short-term investments: Corporate debt securities $ 216.2 $ 0.1 $ (1.3 ) $ 215.0 Municipal obligations 11.1 — (0.1 ) 11.0 Asset-backed securities 63.5 — (0.4 ) 63.1 U.S. government sponsored agencies 80.9 0.2 (0.8 ) 80.3 Foreign government obligations 3.6 — — 3.6 375.3 0.3 (2.6 ) 373.0 Long-term investments: Asset-backed securities 0.2 — — 0.2 0.2 — — 0.2 Total $ 375.5 $ 0.3 $ (2.6 ) $ 373.2
Summary of investments with gross unrealized losses and the associated fair value	The following is a summary of investments with gross unrealized losses and the associated fair value (in millions): December 31, December 31, 2018 Fair value of investments in a loss position 12 months or more $ 19.9 $ 117.9 Fair value of investments in a loss position less than 12 months $ 97.8 $ 193.0 Gross unrealized losses for investments in a loss position 12 months or more $ 0.1 $ 1.8 Gross unrealized losses for investments in a loss position less than 12 months $ 0.3 $ 0.8
Summary of amortized cost and estimated fair value of debt securities by contractual maturity date	The following is a summary of the amortized cost and estimated fair value of our debt securities at December 31, 2019 by contractual maturity date (in millions): Amortized Cost Estimated Fair Value Mature in less than one year $ 174.5 $ 174.6 Mature in one to five years 164.2 165.2 Mature in more than five years 62.2 63.1 Total $ 400.9 $ 402.9
Estimated fair value of financial instruments	The estimated fair value of our debt discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions): December 31, 2019 December 31, 2018 Carrying Amount Estimated Fair Value Fair Value Hierarchy Level Carrying Amount Estimated Fair Value Fair Value Hierarchy Level Total current maturities long-term debt, excluding leases $ 424.4 $ 435.5 2 $ — $ — 2 Total long-term debt, excluding leases and current maturities $ — $ — 2 $ 423.7 $ 435.8 2

4. Intangible Assets, Goodwil_2

4. Intangible Assets, Goodwill and Other (Tables)	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Changes to goodwill by segment	Changes to goodwill by segment were as follows (in millions): 2019 2018 Life Clinical Total Life Clinical Total Balances as of January 1: Goodwill $ 234.5 $ 320.5 $ 555.0 $ 234.7 $ 324.6 $ 559.3 Accumulated impairment losses and write-offs (41.8 ) (293.4 ) (335.2 ) (35.9 ) (17.3 ) (53.2 ) Goodwill, net 192.7 27.1 219.8 198.8 307.3 506.1 Acquisitions 15.6 28.7 44.3 — — — Divestiture — — — — (1.4 ) (1.4 ) Impairment — — — (5.9 ) (276.1 ) (282.0 ) Currency fluctuations — — — (0.2 ) (2.7 ) (2.9 ) Balances as of December 31: Goodwill 250.1 349.2 599.3 234.5 320.5 555.0 Accumulated impairment losses and write-offs (41.8 ) (293.4 ) (335.2 ) (41.8 ) (293.4 ) (335.2 ) Goodwill, net $ 208.3 $ 55.8 $ 264.1 $ 192.7 $ 27.1 $ 219.8
Schedule of Finite-Lived Intangible Assets by Major-Class	Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions): December 31, 2019 Weighted-Average Amortization Period (years) Purchase Price Accumulated Amortization Net Carrying Amount Customer relationships/lists 6.36 $ 107.2 $ (74.3 ) $ 32.9 Know how 5.71 188.5 (162.6 ) 25.9 Developed product technology 8.31 144.2 (93.9 ) 50.3 Licenses 8.74 76.0 (44.4 ) 31.6 Tradenames 8.50 6.4 (3.6 ) 2.8 Covenants not to compete 6.01 3.2 (1.4 ) 1.8 Other — 0.1 (0.1 ) — Total definite-lived intangible assets 525.6 (380.3 ) 145.3 In-process research and development 0.2 — 0.2 Total purchased intangible assets $ 525.8 $ (380.3 ) $ 145.5 December 31, 2018 Weighted-Average Amortization Period (years) Purchase Price Accumulated Amortization Net Carrying Amount Customer relationships/lists 3.98 $ 88.7 $ (68.3 ) $ 20.4 Know how 6.64 190.6 (159.8 ) 30.8 Developed product technology 8.34 130.4 (86.6 ) 43.8 Licenses 9.72 76.3 (40.9 ) 35.4 Tradenames 3.42 3.9 (3.3 ) 0.6 Covenants not to compete 7.01 3.2 (1.1 ) 2.1 Total definite-lived intangible assets $ 493.1 $ (360.0 ) $ 133.1

5. Notes Payable and Long-Ter_2

5. Notes Payable and Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Principal components of long-term debt [Table Text Block]	The principal components of long-term debt are as follows (in millions): December 31, 2019 December 31, 2018 4.875% Senior Notes due 2020, net of discount $ 425.0 $ 425.0 Less unamortized discount and debt issuance costs (0.6 ) (1.3 ) Long-term debt less unamortized discount and debt issuance costs 424.4 423.7 Finance leases and other debt 15.4 — Capital leases and other debt — 15.7 439.8 439.4 Less current maturities (426.2 ) (0.5 ) Long-term debt $ 13.6 $ 438.9

6. Income Taxes (Tables)

6. Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
U.S. and international components of income before taxes [Table Text Block]	The U.S. and international components of income before taxes are as follows (in millions): Year Ended December 31, 2019 2018 2017 U.S. $ 1,034.0 $ 363.4 $ 72.8 International 1,227.1 149.3 25.0 Income before taxes $ 2,261.1 $ 512.7 $ 97.8
Provision for income taxes [Table Text Block]	The provision for income taxes consists of the following (in millions): Year Ended December 31, 2019 2018 2017 Current tax expense: U.S. Federal $ 13.0 $ 8.8 $ 6.7 State 4.4 2.2 3.4 International 23.5 30.5 32.0 Current tax expense 40.9 41.5 42.1 Deferred tax expense (benefit): U.S. Federal 409.7 114.0 (69.8 ) State 24.4 6.6 4.3 International 16.1 0.3 (19.3 ) Deferred tax expense (benefit) 450.2 120.9 (84.8 ) Non-current tax expense (benefit) 11.3 (15.4 ) 18.3 Provision for (benefit from) income taxes $ 502.4 $ 147.0 $ (24.4 )
Reconcilation of effective tax rate on inocme before taxes and statutory rate [Table Text Block]	The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows: Year Ended December 31, 2019 2018 2017 U. S. statutory tax rate 21.0 % 21.0 % 35.0 % Impact of foreign operations (9.7 ) (4.1 ) 6.0 Research tax credits (0.2 ) (0.7 ) (3.8 ) Nontaxable subsidies (0.1 ) (0.2 ) (2.2 ) Goodwill impairment — 5.6 1.2 Share-based compensation (0.1 ) (1.0 ) (5.3 ) Nondeductible executive compensation 0.1 0.2 2.0 U.S. taxation of foreign income 10.3 15.5 2.7 Acquisition-related — (0.2 ) 10.1 U.S. tax reform — (9.6 ) (71.0 ) State taxes 1.0 1.7 2.9 Other (0.1 ) 0.5 (2.6 ) Provision for (benefit from) income taxes 22.2 % 28.7 % (25.0 )%
Significant components of deferred tax assets and liabilities [Table Text Block]	Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of deferred tax assets and liabilities are as follows (in millions): December 31, 2019 2018 Deferred tax assets: Bad debt, inventory and warranty accruals $ 23.9 $ 21.7 Other post-employment benefits, vacation and other reserves 23.0 23.0 Tax credit and net operating loss carryforwards 83.7 75.3 Lease obligations 48.6 — Other 26.0 27.1 Total gross deferred tax assets 205.2 147.1 Valuation allowance (67.2 ) (70.8 ) Total deferred tax assets 138.0 76.3 Deferred tax liabilities: Property and equipment 38.4 40.1 Lease assets 46.4 — Investments and intangible assets 1,001.4 540.6 Total deferred tax liabilities 1,086.2 580.7 Net deferred tax liabilities $ (948.2 ) $ (504.4 )
Tabular reconcilation of total amounts of unrecognized tax benefits [Table Text Block]	The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions): 2019 2018 2017 Unrecognized tax benefits – January 1 $ 29.8 $ 54.9 $ 21.1 Additions to tax positions related to prior years 7.6 0.6 1.3 Reductions to tax positions related to prior years (0.7 ) (20.2 ) (1.0 ) Additions to tax positions related to the current year 3.0 4.6 34.8 Settlements — (6.8 ) (0.2 ) Lapse of statute of limitations (0.4 ) (1.1 ) (3.4 ) Currency translation (0.1 ) (2.2 ) 2.3 Unrecognized tax benefits – December 31 $ 39.2 $ 29.8 $ 54.9

7. Stockholders' Equity Stockho

7. Stockholders' Equity Stockholders' Equity Shares Detail (Tables)	12 Months Ended
	Dec. 31, 2019
Class of Stock [Line Items]
Class of Treasury Stock [Table Text Block]	The share repurchase activity under the share repurchase program through open market transactions in 2018 and 2019 is summarized as follows: Number of Shares Purchased Weighted-Average Price per Share Total Shares Repurchased To Date Remaining Authorized Value (in millions) November 1, 2018 - November 30, 2018 178,911 $ 273.39 193,150 $ 201.1 May 1, 2019 - May 31, 2019 25,421 $ 291.70 218,571 $ 193.7 June 1, 2019 - June 30, 2019 25,977 $ 292.01 244,548 $ 186.1 August 1, 2019 - August 31, 2019 14,745 $ 339.05 259,293 $ 181.1 November 1, 2019 - November 30, 2019 22,343 $ 358.04 281,636 $ 173.1
Schedule of Stock by Class [Table Text Block]	Changes to Bio-Rad's issued common stock shares are as follows (in thousands): Class A Shares Class B Shares Balance at January 1, 2017 24,454 5,124 B to A conversions 34 (34 ) Issuance of common stock 191 18 Balance at December 31, 2017 24,679 5,108 B to A conversions 30 (30 ) Issuance of common stock 175 18 Balance at December 31, 2018 24,884 5,096 B to A conversions 24 (24 ) Issuance of common stock 58 18 Balance at December 31, 2019 24,966 5,090

8. Accumulated Other Comprehe_2

8. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables)	12 Months Ended
	Dec. 31, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Accumulated other comprehensive income (loss) included in our Consolidated Balance Sheets and Consolidated Statements of Changes in Stockholders' Equity consists of the following components (in millions): Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains (losses) on available-for-sale investments Total Accumulated other comprehensive income (loss) Balances as of January 1, 2018 $ 77.4 $ (22.3 ) $ 4.4 $ 59.5 Other comprehensive (loss) income, before reclassifications (112.9 ) 6.9 (1.4 ) (107.4 ) Amounts reclassified from Accumulated other comprehensive income — 2.4 0.3 2.7 Income tax effects — (1.8 ) — (1.8 ) Other comprehensive income (loss), net of income taxes (112.9 ) 7.5 (1.1 ) (106.5 ) Balances as of December 31, 2018 $ (35.5 ) $ (14.8 ) $ 3.3 $ (47.0 ) Other comprehensive (loss) income, before reclassifications (36.5 ) (10.0 ) 4.8 (41.7 ) Amounts reclassified from Accumulated other comprehensive income — 1.5 (0.4 ) 1.1 Income tax effects (0.4 ) 1.1 (0.5 ) 0.2 Other comprehensive (loss) income, net of income taxes (36.9 ) (7.4 ) 3.9 (40.4 ) Balances as of December 31, 2019 $ (72.4 ) $ (22.2 ) $ 7.2 $ (87.4 )

8. Accumulated Other Comprehe_3

8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables)	12 Months Ended
	Dec. 31, 2019
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]	The amounts reclassified out of Accumulated other comprehensive income into the Consolidated Statements of Income, with presentation location, were as follows: December 31, Components of Comprehensive income 2019 2018 Location Amortization of foreign other post-employment benefit items $ (1.5 ) $ (2.4 ) Selling, general and administrative expense Net holding gains (losses) on equity securities and available for sale investments $ 0.4 $ (0.3 ) Other (income) expense, net

9. Share-based Compensation (Ta

9. Share-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement, Noncash Expense [Abstract]
Stock Options Activity	Stock Options The following table summarizes stock option activity: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in millions) Outstanding, December 31, 2018 373,640 $ 138.81 Granted 34,672 $ 328.48 Exercised (55,490 ) $ 98.00 Forfeited/expired (8,300 ) $ 231.71 Outstanding, December 31, 2019 344,522 $ 162.23 4.76 $ 71.6 Unvested, December 31, 2019 94,172 $ 273.93 8.45 $ 9.1 Exercisable, December 31, 2019 250,350 $ 120.22 3.46 $ 62.5
Stock Options Valuation Assumptions	The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions: Year Ended December 31, 2019 2018 2017 Expected volatility 22 % 22 % 20 % Risk-free interest rate 1.69 % 2.85 % 1.87 % Expected life (in years) 7.5 7.6 7.2 Expected dividend — — — Weighted-average fair value of options granted $ 93.96 $ 105.94 $ 58.65
Resticted Stock Activity	The following table summarizes restricted stock unit activity: Restricted Stock Units Weighted- Average Grant-Date Fair Value Weighted-Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in millions) Outstanding, December 31, 2018 474,400 $ 235.58 Granted 174,782 $ 332.38 Vested (134,525 ) $ 206.44 Forfeited (44,715 ) $ 243.76 Outstanding, December 31, 2019 469,942 $ 279.14 2.08 $ 173.9
Employee Stock Purchase Plan, Valuation Assumptions	The fair value of the employees’ purchase rights under the 2011 ESPP was estimated using a Black-Scholes model with the following weighted-average assumptions: Year Ended December 31, 2019 2018 2017 Expected volatility 31 % 27 % 19 % Risk-free interest rate 2.25 % 1.82 % 0.83 % Expected life (in years) 0.24 0.24 0.24 Expected dividend — — — Weighted-average fair value of purchase rights $ 60.39 $ 55.04 $ 38.86

10. Other Income and Expenses

10. Other Income and Expenses (Tables)	12 Months Ended
	Dec. 31, 2019
Other Income and Expenses [Abstract]
Schedule of other income (expense), net	Other (income) expense, net includes the following components (in millions): Year Ended December 31, 2019 2018 2017 Interest and investment income $ (30.5 ) $ (26.6 ) $ (19.1 ) Net realized gains on investments (1.5 ) (1.6 ) (0.1 ) Other-than-temporary impairment losses on investments 5.8 0.8 7.0 Gain on sale of land — (4.1 ) — Gain on divestiture of a product line — (5.1 ) — Other expense 0.1 — 1.5 Other (income) expense, net $ (26.1 ) $ (36.6 ) $ (10.7 )

11. Supplemental Cash Flow I_2

11. Supplemental Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2019
Supplemental Cash Flow Information [Abstract]
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	11. SUPPLEMENTAL CASH FLOW INFORMATION The reconciliation of net income to net cash provided by operating activities is as follows (in millions): Year Ended December 31, 2019 2018 2017 Net income $ 1,758.7 $ 365.6 $ 122.2 Adjustments to reconcile net income to net cash provided by operating activities Depreciation and amortization 134.2 138.1 148.7 Reduction in the carrying amount of right-of-use assets 40.3 — — Share-based compensation 35.6 27.8 23.4 Gains on dispositions of securities (1.5 ) (1.6 ) (0.1 ) Other-than-temporary impairment losses on investments 5.8 0.8 7.0 Changes in fair market value of equity securities (2,031.0 ) (606.2 ) — Losses on dispositions of fixed assets 1.2 2.0 8.1 Gain on sale of land — (4.1 ) — Gain on divestiture of a product line — (5.1 ) — Payments for operating lease liabilities (38.6 ) — — Changes in fair value of contingent consideration (1.6 ) (6.2 ) (18.1 ) Decrease (increase) in accounts receivable, net 1.6 59.7 (64.1 ) Decrease (increase) in inventories, net 24.2 (12.9 ) (47.7 ) Decrease (increase) in other current assets 61.8 (15.3 ) (35.7 ) Increase (decrease) in accounts payable and other current liabilities 10.6 (45.6 ) 7.8 Decrease in income taxes payable (4.2 ) (20.9 ) (22.4 ) Increase (decrease) in deferred income taxes 450.2 120.9 (82.0 ) (Increase) decrease in other long term assets (1.7 ) 1.1 2.3 Increase (decrease) in other long term liabilities 13.4 (10.0 ) 38.1 Impairment losses on goodwill and long-lived assets — 292.5 11.5 Other (1.1 ) 4.9 5.1 Net cash provided by operating activities $ 457.9 $ 285.5 $ 104.1 Non-cash investing activities: Purchased property, plant and equipment $ 8.1 $ 5.7 $ — Purchased marketable securities and investments $ 1.4 $ 0.8 $ 2.8 Sold marketable securities and investments $ 1.3 $ — $ 0.3

12. Commitments & Contingent _2

12. Commitments & Contingent Liabilities Commitments & Contingent Liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Obligations and Funded Status [Abstract]
Schedule of Net Benefit Costs [Table Text Block]	Components of Net Periodic Benefit Cost The following sets forth the net periodic benefit cost (income) for the periods indicated (in millions): 2019 2018 2017 Service costs $6.9 $7.5 $6.5 Interest costs 1.5 1.1 1.1 Expected returns on plan assets (1.2 ) (1.1 ) (1.1 ) Amortization of actuarial losses 1.0 1.3 1.4 Amortization of prior service costs — 0.1 — Settlements 0.9 — 1.2 Net periodic benefit costs $9.1 $8.9 $9.1
Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]	Obligations and Funded Status The following table sets forth the change in benefit obligations, fair value of plan assets and amounts recognized in the Consolidated Balance Sheets for the plans (in millions): Change in benefit obligation: 2019 2018 Benefit obligation at beginning of year $137.3 $136.6 Service cost 6.9 7.5 Interest cost 1.5 1.1 Plan participants' contributions 3.5 3.1 Actuarial (gain) loss 11.9 (5.4 ) Gross benefits paid (2.1 ) (3.1 ) Plan amendments 0.2 (0.5 ) Settlements (3.8 ) — Change attributable to foreign exchange (1.6 ) (2.0 ) Benefit obligation at end of year 153.8 137.3 Change in plan assets: Fair value of plan assets at beginning year 66.9 61.7 Actual return on plan assets 0.9 0.3 Employer contributions 4.7 4.0 Plan participants' contributions 3.8 3.1 Gross benefits paid (0.8 ) (1.5 ) Settlements (3.8 ) — Change attributable to foreign exchange 0.6 (0.7 ) Fair value of plan assets at end of year 72.3 66.9 Under funded status of plans $(81.5) $(70.4) Amounts recognized in the consolidated balance sheets: Current liabilities (Accrued payroll and employee benefits) $(1.1) $(1.1) Noncurrent liabilities (Other long-term liabilities) (80.4 ) (69.3 ) Net liability, end of fiscal year $(81.5) $(70.4)
Defined Benefit Plan, Assumptions [Table Text Block]	Assumptions The weighted-average assumptions used in computing the benefit obligations are as follows: 2019 2018 Discount rate 0.5 % 1.1 % Compensation rate increase 1.7 % 1.8 % The weighted-average assumptions used in computing the net periodic benefit costs are as follows: 2019 2018 2017 Discount rate 1.1 % 0.8 % 0.9 % Expected long-term rate of return on plan assets 1.8 % 1.8 % 1.9 %

14. Segment Reporting (Tables)

14. Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Information regarding industry segments	Information regarding industry segments at December 31, 2019 , 2018 , and 2017 and for the years then ended is as follows (in millions): Life Science Clinical Diagnostics Other Operations Segment net sales 2019 $ 885.9 $ 1,412.0 $ 13.8 2018 861.7 1,411.8 15.9 2017 785.2 1,360.8 14.2 Allocated interest expense 2019 $ 7.4 $ 15.9 $ 0.1 2018 7.2 16.7 0.1 2017 7.0 14.9 — Depreciation and amortization 2019 $ 29.4 $ 71.7 $ 0.9 2018 34.1 72.0 0.5 2017 36.2 80.2 — Segment profit (loss) 2019 $ 72.1 $ 148.5 $ (1.5 ) 2018 28.7 (145.7 ) 0.2 2017 (9.9 ) 114.8 1.4 Segment assets 2019 $ 496.1 $ 1,075.8 $ 9.2 2018 450.2 949.0 5.9 Capital expenditures 2019 $ 16.6 $ 58.9 $ 0.6 2018 36.7 60.5 0.5
Reconciliation of segment profit to consolidated income before taxes	he following reconciles total segment profit to consolidated income before taxes (in millions): Year Ended December 31, 2019 2018 2017 Total segment profit (loss) $ 219.1 $ (116.8 ) $ 106.3 Foreign currency exchange losses, net (2.2 ) (2.9 ) (9.1 ) Net corporate operating, interest and other expense not allocated to segments (12.9 ) (10.4 ) (10.1 ) Change in fair market value of equity securities 2,031.0 606.2 — Other income (expense), net 26.1 36.6 10.7 Consolidated income before income taxes $ 2,261.1 $ 512.7 $ 97.8
Reconciliation of Assets from Segment to Consolidated	The following reconciles total segment assets to consolidated total assets (in millions): December 31, 2019 2018 Total segment assets $ 1,581.1 $ 1,405.1 Cash and other current assets 1,233.5 1,047.2 Property, plant and equipment, net, and operating lease right-of-use assets, excluding segment specific balances 66.8 79.9 Goodwill, net 264.1 219.8 Other long-term assets 4,863.4 2,859.1 Total assets $ 8,008.9 $ 5,611.1
Net sales and assets to external customers by geographic area	The following presents net sales to external customers by geographic region based primarily on the location of the use of the product or service (in millions): Year Ended December 31, 2019 2018 2017 Europe $ 770.3 $ 792.0 $ 758.5 Asia 505.0 495.5 461.3 United States 899.1 863.6 800.2 Other (primarily Canada and Latin America) 137.3 138.3 140.0 Total net sales $ 2,311.7 $ 2,289.4 $ 2,160.2 The following presents Property, plant and equipment, net, Operating lease right-of-use assets and Other assets, excluding deferred income taxes, by geographic region based upon the location of the asset (in millions): December 31, 2019 2018 Europe $ 198.3 $ 129.1 Asia 51.5 20.7 United States 468.7 369.2 Other (primarily Canada and Latin America) 12.7 11.1 Total Property, plant and equipment, net, Operating lease right-of-use assets and Other assets, excluding deferred income taxes $ 731.2 $ 530.1 Prior year amounts have been adjusted to exclude Other investments.

15. Restructuring Costs (Tables

15. Restructuring Costs (Tables)	12 Months Ended
	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs [Table Text Block]	The following table summarizes the activity of our European and North American reorganization restructuring reserves for severance (in millions): 2019 Life Science Clinical Diagnostics Total Balance as of January 1 $ — $ — $ — Charged to expense 6.2 19.1 25.3 Cash payments (0.4 ) (0.7 ) (1.1 ) Reserve transferred from European Reorganization restructuring costs reserve (see above) 0.3 0.4 0.7 Foreign currency translation losses 0.1 0.3 0.4 Balance as of December 31 $ 6.2 $ 19.1 $ 25.3 The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions): 2019 2018 Life Science Clinical Diagnostics Total Life Science Clinical Diagnostics Total Balance as of January 1 $ 0.6 $ 1.0 $ 1.6 $ 2.2 $ 4.1 $ 6.3 Adjustment to expense — (0.1 ) (0.1 ) (0.1 ) (0.1 ) (0.2 ) Cash payments (0.3 ) (0.5 ) (0.8 ) (1.5 ) (2.9 ) (4.4 ) Reserve transferred to European and North American Reorganization restructuring costs reserve (see below) (0.3 ) (0.4 ) (0.7 ) — — — Foreign currency translation gains — — — — (0.1 ) (0.1 ) Balance as of December 31 $ — $ — $ — $ 0.6 $ 1.0 $ 1.6 The following table summarizes the activity for the termination of the diagnostics research and development project and the facility closures restructuring reserves for severance and exit costs (in millions): 2019 2018 Balance as of January 1 $ 11.5 $ 14.1 Charged to expense — 5.8 Adjustment to expense (0.4 ) 0.3 Cash payments (7.7 ) (8.4 ) Foreign currency translation gains (0.2 ) (0.3 ) Balance as of December 31 $ 3.2 $ 11.5

16. Leases (Tables)

16. Leases (Tables)	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Lease, Cost [Table Text Block]	The components of lease expense were as follows (in millions): Twelve Months Ended December 31, 2019 Operating lease cost $ 51.4 Finance lease cost: Amortization of right-to-use assets $ 0.6 Interest on lease liabilities 0.9 Total finance lease cost $ 1.5 Sublease income $ 3.0
Lessee Supplemental Cash Flow Information [Table Text Block]	Supplemental cash flow information related to leases was as follows (in millions): Twelve Months Ended December 31, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 47.2 Operating cash flows from finance leases $ 0.9 Financing cash flows from finance leases $ 0.6 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 28.7 Finance leases $ 0.2
Lessee Supplemental Balance Sheet Information [Table Text Block]	Supplemental balance sheet information related to leases was as follows (in millions): December 31, 2019 Operating Leases Operating lease right-of-use assets $ 201.9 Current operating lease liabilities $ 35.4 Operating lease liabilities 176.0 Total operating lease liabilities $ 211.4 December 31, 2019 Finance Leases Property, plant and equipment, gross $ 11.4 Less: accumulated depreciation and amortization (4.2 ) Property, plant and equipment, net $ 7.2 Current maturities of long-term debt and notes payable $ 0.5 Long-term debt, net of current maturities 11.2 Total finance lease liabilities $ 11.7 December 31, 2019 Weighted Average Remaining Lease Term Operating leases - in years 9 Finance leases - in years 18 Weighted Average Discount Rate Operating leases 4.2 % Finance leases 6.5 %
Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block]	Maturities of lease liabilities were as follows (in millions): Year Ending December 31, Operating Leases Finance Leases 2020 $ 41.0 $ 1.1 2021 35.8 1.3 2022 28.6 1.2 2023 24.5 1.1 2024 21.8 1.1 Thereafter 103.7 15.2 Total lease payments 255.4 21.0 Less imputed interest (44.0 ) (9.3 ) Total $ 211.4 $ 11.7

17. Quarterly Financial Data (T

17. Quarterly Financial Data (Tables)	12 Months Ended
	Dec. 31, 2019
Quarterly Financial Data [Abstract]
Schedule of Quarterly Financial Data [Table Text Block]	First Quarter Second Quarter Third Quarter Fourth Quarter 2019 Net sales $ 554.0 $ 572.6 $ 560.6 $ 624.5 Gross profit 311.8 307.8 307.0 330.4 Net income (loss) 865.2 598.8 (258.8 ) 553.5 Basic earnings (loss) per share $ 29.03 $ 20.08 $ (8.68 ) $ 18.50 Diluted earnings (loss) per share $ 28.74 $ 19.86 $ (8.68 ) $ 18.31 2018 Net sales $ 551.5 $ 575.9 $ 545.1 $ 616.9 Gross profit 302.2 301.7 286.7 332.6 Net income (loss) 656.8 268.0 269.3 (828.5 ) Basic earnings (loss) per share $ 22.05 $ 8.99 $ 9.02 $ (27.73 ) Diluted earnings (loss) per share $ 21.77 $ 8.87 $ 8.89 $ (27.73 )

1. Significant Accounting Pol_4

1. Significant Accounting Policies Property, Plant and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Restricted investments	$ 5,560	$ 5,560
Retained earnings	5,470,779	3,722,073
Other assets	79,636	70,298
Prepaid Taxes	5,400
Equipment	1,015,359	970,081
Deferred income taxes	997,787	553,239
Income Tax Expense (Benefit)	$ (502,406)	$ (147,045)	$ 24,444
Minimum [Member] | Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Minimum [Member] | Building and Building Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Minimum [Member] | Reagent Rental Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	1 year
Minimum [Member] | Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member] | Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	12 years
Maximum [Member] | Building and Building Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	39 years
Maximum [Member] | Reagent Rental Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Maximum [Member] | Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	12 years

1. Significant Accounting Pol_5

1. Significant Accounting Policies Warranty rollforward (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Movement in Standard Product Warranty Accrual [Roll Forward]
Warranty accrual, beginning of period	$ 10.1	$ 18.7
Provision for warranty	9.9	25.5
Actual warranty costs	(11)	(34.1)
Warranty accrual, end of period	$ 9	$ 10.1

1. Significant Accounting Pol_6

1. Significant Accounting Policies Earnings per share (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Basic weighted average shares outstanding	29,843	29,836	29,655
Effect of potentially dilutive stock options and restricted stock awards	341	392	379
Diluted weighted average common shares	30,184	30,228	30,034
Anti-dilutive shares excluded from the computation of diluted EPS	98	84	13

1. Significant Accounting Pol_7

1. Significant Accounting Policies Details (Details) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2019USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Interest expense		$ 23,416	$ 23,962	$ 23,014
Selling, general and administrative expense		824,625	834,783	806,790
Research and development expense		202,710	199,196	250,157
Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit)				70,000
Stockholders' Equity Attributable to Parent	$ 5,755,057	5,755,057	4,020,331	2,930,250	$ 2,579,160
Restricted investments	5,560	5,560	5,560
Retained earnings	5,470,779	5,470,779	3,722,073
Prepaid Taxes	(5,400)	(5,400)
Accumulated other comprehensive (loss) income	(87,348)	(87,348)	(46,958)
Other (income) expense, net		26,094	36,593	10,697
Deferred Tax Assets, Gross	205,200	$ 205,200	147,100
Document Fiscal Year Focus		2019
Unrealized Gain on Securities	646,000	$ 2,030,987	606,230	0
Deferred Income Tax Expense (Benefit)		450,200	120,900	(84,800)
Cost of Goods and Services Sold		1,054,663	1,066,264	$ 972,450
Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Increase			$ (49,000)
Adjustments for New Accounting Pronouncement [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Capitalized Cloud Computing Arrangements	$ 3,100	$ 3,100
541714 Research and Development in Biotechnology (except Nanobiotechnology) [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Entity Number of Employees	780	780

1. Significant Accounting Pol_8

1. Significant Accounting Policies Revenue Recognition (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jan. 01, 2018
Disaggregation of Revenue [Line Items]
Cost of Goods and Services Sold	$ 1,054,663	$ 1,066,264	$ 972,450
Retained earnings	$ 5,470,779	$ 3,722,073
Revenue Allocation Percent To Lease Elements	3.00%	5.00%
Deferred Revenue	$ 45,800	$ 37,300
Deferred Revenue, Period Increase (Decrease)	33,100
Deferred Revenue, Revenue Recognized	$ 24,600
Accounting Standards Update 2014-09 [Member]
Disaggregation of Revenue [Line Items]
Retained earnings				$ 100

2. Acquisitions (Details)

2. Acquisitions (Details) - USD ($) $ in Thousands	3 Months Ended				12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Oct. 01, 2019	Aug. 02, 2019	Mar. 04, 2019	Dec. 31, 2017
Business Acquisition [Line Items]
Business Combination, Consideration Transferred	$ 4,200	$ 60,000	$ 20,000
Payments to Acquire Businesses, Net of Cash Acquired	3,600	59,700	16,000	$ 4,000
Business Combination, Contingent Consideration, Liability							$ 600
Business Combination, Separately Recognized Transactions, Revenues and Gains Recognized	400
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles							3,400	$ 26,800	$ 5,500
Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets	200				$ 200
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets									$ 200
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net							$ 1,400	$ 4,200
Goodwill	264,131			$ 219,770	264,131	$ 219,770				$ 506,100
Goodwill, Acquired During Period		$ 28,700	15,600		44,300	$ 0
Business Combination, Consideration Transferred, Liabilities Incurred	800		$ 1,300
Analytical Flow Cytometer Platform [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability	$ 4,300				$ 4,300

3. Fair Value Measurements (Det

3. Fair Value Measurements (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2019	Oct. 01, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities, FV-NI, Unrealized Gain		$ 2,031.1
Debt Securities, Available-for-sale		402.9
Business Combination, Contingent Consideration, Liability			$ 0.6
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		5.6		$ 5.6
Equity Securities, FV-NI		4,664.4		2,672.9
Debt Securities, Available-for-sale		402.9		373.2
Forward foreign exchange contracts, Asset	[1]	0.9		0.6
Financial Assets Carried at Fair Value		5,227.9		3,200
Forward foreign exchange contracts, Liability	[2]	1		0.7
Business Combination, Contingent Consideration, Liability	[3]	4.9		8.4
Liabilities, Fair Value Disclosure		5.9		9.1
Fair Value, Recurring [Member] | Foreign Government Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		3.1
Fair Value, Recurring [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		204.5		215
Fair Value, Recurring [Member] | US Government Sponsored Agencies [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		106.1		80.3
Fair Value, Recurring [Member] | Foreign Government Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		4.7		3.6
Fair Value, Recurring [Member] | Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		11.6		11
Fair Value, Recurring [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		72.9		63.3
Fair Value, Recurring [Member] | Time Deposits [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	41.2		32.7
Fair Value, Recurring [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	69.9		36.9
Fair Value, Recurring [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	42.9		77.8
Fair Value, Recurring [Member] | Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	154.1		147.7
Fair Value, Recurring [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		0.1		0.3	[4]
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		5.6		5.6
Equity Securities, FV-NI		4,664.4		2,672.9
Debt Securities, Available-for-sale		0		0
Forward foreign exchange contracts, Asset	[1]	0		0
Financial Assets Carried at Fair Value		4,771.1		2,738.1
Forward foreign exchange contracts, Liability	[2]	0		0
Business Combination, Contingent Consideration, Liability	[3]	0		0
Liabilities, Fair Value Disclosure		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Foreign Government Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | US Government Sponsored Agencies [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Foreign Government Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Time Deposits [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	31.2		22.7
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	69.9		36.9
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	101.1		59.6
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		0		0
Equity Securities, FV-NI		0		0
Debt Securities, Available-for-sale		402.9		373.2
Forward foreign exchange contracts, Asset	[1]	0.9		0.6
Financial Assets Carried at Fair Value		456.8		461.9
Forward foreign exchange contracts, Liability	[2]	1		0.7
Business Combination, Contingent Consideration, Liability	[3]	0		0
Liabilities, Fair Value Disclosure		1		0.7
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Foreign Government Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		3.1
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		204.5		215
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | US Government Sponsored Agencies [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		106.1		80.3
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Foreign Government Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		4.7		3.6
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		11.6		11
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		72.9		63.3
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Time Deposits [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	10		10
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	42.9		77.8
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	53		88.1
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		0.1		0.3
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		0		0
Equity Securities, FV-NI		0		0
Debt Securities, Available-for-sale		0		0
Forward foreign exchange contracts, Asset	[1]	0		0
Financial Assets Carried at Fair Value		0		0
Forward foreign exchange contracts, Liability	[2]	0		0
Business Combination, Contingent Consideration, Liability	[3]	4.9		8.4
Liabilities, Fair Value Disclosure		4.9		8.4
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Foreign Government Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | US Government Sponsored Agencies [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Foreign Government Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Time Deposits [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	[4]	0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		0		0
Other Current Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		3.3		3.2
Short-term Investments [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities, FV-NI		51		40.2
Debt Securities, Available-for-sale		402.8		373
Short-term Investments [Member] | Fair Value, Recurring [Member] | Foreign Government Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		3.1
Short-term Investments [Member] | Fair Value, Recurring [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		204.5		215
Short-term Investments [Member] | Fair Value, Recurring [Member] | US Government Sponsored Agencies [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		106.1		80.3
Short-term Investments [Member] | Fair Value, Recurring [Member] | Foreign Government Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		4.7		3.6
Short-term Investments [Member] | Fair Value, Recurring [Member] | Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		11.6		11
Short-term Investments [Member] | Fair Value, Recurring [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		72.8		63.1
Other Investments [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities, FV-NI		4,613.4		2,632.7
Debt Securities, Available-for-sale		0.1		0.2
Other Noncurrent Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		$ 1.6		$ 5.2
[1]	Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets.
[2]	Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets.
[3]	Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions): December 31, 2019 December 31, 2018 Other current liabilities $ 3.3 $ 3.2 Other long-term liabilities 1.6 5.2 Total $ 4.9 $ 8.4
[4]	(a) Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets.

3. Fair Value Measurements Fore

3. Fair Value Measurements Foreign Exchange Forward Contracts (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)
Forward foreign exchange contract to purchase foreign currency [Member]
Derivatives, Fair Value [Line Items]
Gain (loss) on foreign currency derivative instruments not designated as hedging instruments	$ (0.3)
Derivative, Notional Amount	269.1
Forward foreign exchange contract to sell foreign currency [Member]
Derivatives, Fair Value [Line Items]
Gain (loss) on foreign currency derivative instruments not designated as hedging instruments	0.3
Derivative, Notional Amount	$ 52

3. Fair Value Measurements Avai

3. Fair Value Measurements Available-for-Sale Investments (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	$ 400.9
Debt Securities, Available-for-sale	402.9
Fair Value, Recurring [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	402.9	$ 373.2
Fair Value, Recurring [Member] | Corporate Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	204.5	215
Fair Value, Recurring [Member] | Municipal Obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	11.6	11
Fair Value, Recurring [Member] | Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	72.9	63.3
Fair Value, Recurring [Member] | US Government Sponsored Agencies [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	106.1	80.3
Fair Value, Recurring [Member] | Foreign Government Obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	4.7	3.6
Fair Value, Recurring [Member] | Foreign Government Debt [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	3.1
Fair Value, Recurring [Member] | Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	400.9	375.5
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	2.4	0.3
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(0.4)	(2.6)
Debt Securities, Available-for-sale	402.9	373.2
Fair Value, Recurring [Member] | Short-term Investments [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	402.8	373
Fair Value, Recurring [Member] | Short-term Investments [Member] | Corporate Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	203.2	216.2
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	1.4	0.1
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(0.1)	(1.3)
Debt Securities, Available-for-sale	204.5	215
Fair Value, Recurring [Member] | Short-term Investments [Member] | Municipal Obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	11.5	11.1
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	0.1	0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	0	(0.1)
Debt Securities, Available-for-sale	11.6	11
Fair Value, Recurring [Member] | Short-term Investments [Member] | Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	72.7	63.5
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	0.2	0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(0.1)	(0.4)
Debt Securities, Available-for-sale	72.8	63.1
Fair Value, Recurring [Member] | Short-term Investments [Member] | US Government Sponsored Agencies [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	105.6	80.9
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	0.7	0.2
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(0.2)	(0.8)
Debt Securities, Available-for-sale	106.1	80.3
Fair Value, Recurring [Member] | Short-term Investments [Member] | Foreign Government Obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	4.7	3.6
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	0	0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	0	0
Debt Securities, Available-for-sale	4.7	3.6
Fair Value, Recurring [Member] | Short-term Investments [Member] | Foreign Government Debt [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	3.1
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	0
Debt Securities, Available-for-sale	3.1
Fair Value, Recurring [Member] | Short-term Investments [Member] | Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	400.8	375.3
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	2.4	0.3
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(0.4)	(2.6)
Debt Securities, Available-for-sale	402.8	373
Fair Value, Recurring [Member] | Other Long-term Investments [Member] | Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	0.1	0.2
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	0	0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	0	0
Debt Securities, Available-for-sale	0.1	0.2
Fair Value, Recurring [Member] | Other Long-term Investments [Member] | Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	0.1	0.2
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	0	0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	0	0
Debt Securities, Available-for-sale	$ 0.1	$ 0.2

3. Fair Value Measurements Amor

3. Fair Value Measurements Amortized Cost and Fair Value of Debt Securities (Details) $ in Millions	Dec. 31, 2019USD ($)
Fair Value Disclosures [Abstract]
Mature in less than one year	$ 174.5
Mature in one to five years	164.2
Mature in more than five years	62.2
Total Amortized Cost	400.9
Mature in less than one year	174.6
Mature in one to five years	165.2
Mature in more than five years	63.1
Estimated Fair Value	$ 402.9

3. Fair Value Measurements Fair

3. Fair Value Measurements Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Price Change Debt Security	5.00%
Tolerable variance Level 2 debt security pricing	1.00%
Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value	$ 19.9	$ 117.9
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	97.8	193
Gross unrealized losses for investments in a loss position 12 months or more	0.1	1.8
Gross unrealized losses for investments in a loss position less than 12 months	$ 0.3	$ 0.8

3. Fair Value Investments (Deta

3. Fair Value Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Jan. 01, 2018
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Equity Securities without Readily Determinable Fair Value, Amount	$ 300	$ 600	$ 864,490
Investment ownership percentage	37.00%
Carrying (Reported) Amount, Fair Value Disclosure [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt, Current	$ 424,400	0
Total long-term debt, excluding leases and current maturities	0	423,700
Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Short-term Debt, Fair Value	435,500	0
Total long-term debt, excluding leases and current maturities	$ 0	$ 435,800

3. Fair Value Measurements Cont

3. Fair Value Measurements Contingent Consideration (Details) - USD ($) $ in Millions		3 Months Ended			12 Months Ended			37 Months Ended
		Dec. 31, 2019	Sep. 30, 2019	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2019	Oct. 01, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value		$ 4.9			$ 4.9	$ 8.4		$ 4.9
Business Combination, Contingent Consideration, Liability									$ 0.6
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability					(1.6)	(6.2)	$ (18.1)
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	[1]	4.9			4.9	$ 8.4		4.9
Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		4.3			4.3			4.3
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements			$ (1.1)	$ (1.4)	(2.5)
Net (decrease) increase in estimated fair value of contingent consideration included in selling, general and administrative expense					(1.6)			(13.9)
Distributor [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value		0.6			0.6			0.6
Business Combination, Contingent Consideration, Liability		0.6			0.6			$ 0.6
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements		$ (0.7)			$ (1.4)
Discount rate [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate					11.10%
Sales milestone percentage of annual invoices [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Contingent Consideration, Potential Percentage Payout		39.00%			39.00%			39.00%
Sales milestone percentage of annual invoices low [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Contingent Consideration, Potential Percentage Payout		20.00%			20.00%			20.00%
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low		$ 0			$ 0			$ 0
Cost of debt [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate					3.90%
[1]	Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions): December 31, 2019 December 31, 2018 Other current liabilities $ 3.3 $ 3.2 Other long-term liabilities 1.6 5.2 Total $ 4.9 $ 8.4

4. Goodwill and other Purchased

4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other (Details) - USD ($) $ in Thousands	3 Months Ended			12 Months Ended
	Sep. 30, 2019	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Mar. 04, 2019
Goodwill [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill						$ 200
Goodwill [Roll Forward]
Goodwill period start		$ 555,000	$ 559,300	$ 555,000	$ 559,300
Accumulated impairment loss period start		(335,200)	(53,200)	(335,200)	(53,200)
Goodwill, net period start		219,770	506,100	219,770	506,100
Goodwill, Acquired During Period	$ 28,700	15,600		44,300	0
Goodwill, Written off Related to Sale of Business Unit				0	(1,400)
Goodwill, Impairment Loss				0	282,000
Currency fluctuations				0	(2,900)
Goodwill period end				599,300	555,000
Accumulated impairment loss period end				(335,200)	(335,200)
Goodwill, net period end				264,131	219,770
Life Science [Member]
Goodwill [Roll Forward]
Goodwill period start		234,500	234,700	234,500	234,700
Accumulated impairment loss period start		(41,800)	(35,900)	(41,800)	(35,900)
Goodwill, net period start		192,700	198,800	192,700	198,800
Goodwill, Acquired During Period				15,600	0
Goodwill, Written off Related to Sale of Business Unit				0	0
Goodwill, Impairment Loss				0	5,900
Currency fluctuations				0	(200)
Goodwill period end				250,100	234,500
Accumulated impairment loss period end				(41,800)	(41,800)
Goodwill, net period end				208,300	192,700
Clinical Diagnostics [Member]
Goodwill [Roll Forward]
Goodwill period start		320,500	324,600	320,500	324,600
Accumulated impairment loss period start		(293,400)	(17,300)	(293,400)	(17,300)
Goodwill, net period start		$ 27,100	307,300	27,100	307,300
Goodwill, Acquired During Period				28,700	0
Goodwill, Written off Related to Sale of Business Unit			$ (1,400)	0	(1,400)
Goodwill, Impairment Loss				0	276,100
Currency fluctuations				0	(2,700)
Goodwill period end				349,200	320,500
Accumulated impairment loss period end				(293,400)	(293,400)
Goodwill, net period end				$ 55,800	27,100
Pasteur Sanofi Diagnosics S.A. [Member] | Clinical Diagnostics [Member]
Goodwill [Roll Forward]
Goodwill, Impairment Loss					18,100
DiaMed [Member] | Clinical Diagnostics [Member]
Goodwill [Roll Forward]
Goodwill, Impairment Loss					247,200
Biotest AG [Member] | Clinical Diagnostics [Member]
Goodwill [Roll Forward]
Goodwill, Impairment Loss					$ 10,800

4. Goodwill and other Purchas_2

4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Oct. 01, 2019	Aug. 02, 2019	Mar. 04, 2019
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					$ 3,400	$ 26,800	$ 5,500
Finite-Lived Intangible Assets, Gross	$ 493,100	$ 525,600	$ 493,100
Future Amortization Expense, Year One		23,500
Future Amortization Expense, Year Two		22,800
Future Amortization Expense, Year Three		19,600
Future Amortization Expense, Year Four		18,700
Future Amortization Expense, Year Five		16,600
Finite-Lived Intangible Assets, Amortization Expense, after Year Five		44,100
Finite-Lived Intangible Assets, Net [Abstract]
Accumulated Amortization	(360,000)	(380,300)	(360,000)
Net Carrying Amount	133,100	145,300	133,100
Amortization [Abstract]
Amortization expense		23,500	28,300	$ 30,800
Impairment losses on goodwill and long-lived assets	292,500	0	292,513	$ 11,506
Intangible Assets, Net (Excluding Goodwill)	133,123	145,525	$ 133,123
Intangible Assets, Gross (Excluding Goodwill)		$ 525,800
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						16,100
Finite-Lived Intangible Assets, Remaining Amortization Period		6 years	3 years
Finite-Lived Intangible Assets, Gross	88,700	$ 107,200	$ 88,700
Finite-Lived Intangible Assets, Net [Abstract]
Accumulated Amortization	(68,300)	(74,300)	(68,300)
Net Carrying Amount	20,400	$ 32,900	$ 20,400
Know how [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period		5 years	6 years
Finite-Lived Intangible Assets, Gross	190,600	$ 188,500	$ 190,600
Finite-Lived Intangible Assets, Net [Abstract]
Accumulated Amortization	(159,800)	(162,600)	(159,800)
Net Carrying Amount	30,800	$ 25,900	$ 30,800
Developed Technology Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						8,100
Finite-Lived Intangible Assets, Remaining Amortization Period		8 years	8 years
Finite-Lived Intangible Assets, Gross	130,400	$ 144,200	$ 130,400
Finite-Lived Intangible Assets, Net [Abstract]
Accumulated Amortization	(86,600)	(93,900)	(86,600)
Net Carrying Amount	43,800	$ 50,300	$ 43,800
Licensing Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period		8 years	9 years
Finite-Lived Intangible Assets, Gross	76,300	$ 76,000	$ 76,300
Finite-Lived Intangible Assets, Net [Abstract]
Accumulated Amortization	(40,900)	(44,400)	(40,900)
Net Carrying Amount	35,400	$ 31,600	$ 35,400
Trade Names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						2,500
Finite-Lived Intangible Assets, Remaining Amortization Period		8 years	3 years
Finite-Lived Intangible Assets, Gross	3,900	$ 6,400	$ 3,900
Finite-Lived Intangible Assets, Net [Abstract]
Accumulated Amortization	(3,300)	(3,600)	(3,300)
Net Carrying Amount	600	$ 2,800	$ 600
Noncompete Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period		6 years	7 years
Finite-Lived Intangible Assets, Gross	3,200	$ 3,200	$ 3,200
Finite-Lived Intangible Assets, Net [Abstract]
Accumulated Amortization	(1,100)	(1,400)	(1,100)
Net Carrying Amount	$ 2,100	$ 1,800	$ 2,100
Other Intangible Assets [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						$ 100
Finite-Lived Intangible Assets, Remaining Amortization Period		0 years	0 years
Finite-Lived Intangible Assets, Gross		$ 100
Finite-Lived Intangible Assets, Net [Abstract]
Accumulated Amortization		(100)
Net Carrying Amount		0
Life Science [Member] | CellSorter [Member] | Developed Technology Rights [Member]
Amortization [Abstract]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)			$ 8,800
Life Science [Member] | CellSorter [Member] | Noncompete Agreements [Member]
Amortization [Abstract]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)			$ 1,700
In Process Research and Development [Member]
Amortization [Abstract]
Indefinite-lived Intangible Assets (Excluding Goodwill)		$ 200

5. Notes Payable and Long-Ter_3

5. Notes Payable and Long-Term Debt (Details) - USD ($)	Dec. 31, 2019	Apr. 30, 2019	Dec. 31, 2018	Dec. 31, 2010
Debt Instrument [Line Items]
Debt and Lease Obligation	$ 439,800,000		$ 439,400,000
Other Long-term Debt, Current	426,200,000		500,000
Long-term Debt and Lease Obligation	13,579,000		438,937,000
Maturities of Long-term Debt [Abstract]
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months	426,800,000
Long-term Debt, Maturities, Repayments of Principal in Year Two	1,600,000
Long-term Debt, Maturities, Repayments of Principal in Year Three	1,500,000
Long-term Debt, Maturities, Repayments of Principal in Year Four	400,000
Long-term Debt, Maturities, Repayments of Principal in Year Five	400,000
Long-term Debt, Maturities, Repayments of Principal after Year Five	9,700,000
Line of Credit Facility, Remaining Borrowing Capacity	207,500,000
Letters of Credit Outstanding, Amount	4,200,000
Performance Guarantee [Member]
Maturities of Long-term Debt [Abstract]
Letters of Credit Outstanding, Amount	4,200,000
Unsecured Debt [Member] | Senior Notes 4.875% due 2020 [Member]
Debt Instrument [Line Items]
Unsecured Debt	425,000,000		425,000,000
Long-term debt	424,400,000		423,700,000	$ 422,600,000
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	600,000		1,300,000
Debt Instrument, Interest Rate, Effective Percentage				4.946%
Face amount of debt sold				$ 425,000,000
Debt Instrument, Interest Rate, Stated Percentage				4.875%
Finance Lease Obligations [Member] | Finance Leases and Other Debt [Member]
Debt Instrument [Line Items]
Other Long-term Debt	15,400,000		0
Capital Lease Obligations [Member] | Capital Leases and Other Debt [Member]
Debt Instrument [Line Items]
Long-term Debt and Lease Obligation, Including Current Maturities	0		$ 15,700,000
Line of Credit [Member]
Maturities of Long-term Debt [Abstract]
Line of Credit Facility, Maximum Borrowing Capacity		$ 200,000,000
Long-term Line of Credit	$ 0
Line of Credit Facility, Interest Rate at Period End	3.035%
Letters of Credit Outstanding, Amount	$ 200,000

6. Income Taxes (Details)

6. Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Taxes [Line Items]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 3,600
Prepaid Taxes	5,400
U.S.	1,034,000	$ 363,400	$ 72,800
International	1,227,100	149,300	25,000
Income before income taxes	2,261,081	512,659	97,805
U.S. Federal	13,000	8,800	6,700
State	4,400	2,200	3,400
International	23,500	30,500	32,000
Current Income Tax Expense (Benefit)	40,900	41,500	42,100
U.S. Federal	409,700	114,000	(69,800)
State	24,400	6,600	4,300
International	16,100	300	(19,300)
Deferred tax benefit	450,200	120,900	(84,800)
Non-current tax expense (benefit)	11,300	(15,400)	18,300
Provision for income taxes	$ 502,406	$ 147,045	$ (24,444)
U.S. statutory tax rate	21.00%	21.00%	35.00%
Impact of foreign operations	(9.70%)	(4.10%)	6.00%
Research tax credits	(0.20%)	(0.70%)	(3.80%)
Nontaxable subsidies	(0.10%)	(0.20%)	(2.20%)
Goodwill impairment	0.00%	5.60%	1.20%
Stock-based compensation	(0.10%)	(1.00%)	(5.30%)
Nondeductible executive compensation	0.10%	0.20%	2.00%
State taxes	1.00%	1.70%	2.90%
Other	(0.10%)	0.50%	(2.60%)
Provision for income taxes	22.20%	28.70%	(25.00%)
Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit)			$ 70,000
Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Increase		$ (49,000)
Bad debt, inventory and warranty accruals	$ 23,900	21,700
Other post-employment benefits, vacation and other reserves	23,000	23,000
Tax credit and net operating loss carryforwards	83,700	75,300
Other	26,000	27,100
Total gross deferred tax assets	205,200	147,100
Valuation allowance	(67,200)	(70,800)
Total deferred tax assets	138,000	76,300
Property and equipment	38,400	40,100
Investments and intangible assets	1,001,400	540,600
Total deferred tax liabilities	1,086,200	580,700
Net deferred tax liabilities	(948,200)	(504,400)
Unrecognized tax benefits period start	29,800	54,900	21,100
Additions to tax positions related to prior years	7,600	600	1,300
Reductions to tax positions related to prior years	(700)	(20,200)	(1,000)
Additions to tax positions related to the current year	3,000	4,600	34,800
Settlements	0	(6,800)	(200)
Lapse of statute of limitations	(400)	(1,100)	(3,400)
Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation			2,300
Currency translation	(100)	(2,200)
Unrecognized tax benefits period end	39,200	29,800	54,900
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	11,200	9,500	10,900
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense	1,700	$ (1,400)	$ (900)
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit	2,800
Foreign Tax Authority [Member]
Income Taxes [Line Items]
Operating Loss Carryforward With No Expiration Date	$ 124,700
Domestic Tax Authority [Member]
Income Taxes [Line Items]
Other reconciling items	10.30%	15.50%	2.70%
Tax Cuts and Jobs Act [Member]
Income Taxes [Line Items]
U.S. tax reform	0.00%	(9.60%)	(71.00%)
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	$ 239,000
Including accrued interest and penalties [Member]
Income Taxes [Line Items]
Other	1,400
Unrecognized tax benefits period end	50,400
Research Tax Credit Carryforward [Member] | State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Deferred Tax Assets, Tax Credit Carryforwards, Research	$ 35,700
Acquisition-related Costs [Member]
Income Taxes [Line Items]
Other reconciling items	0.00%	(0.20%)	10.10%
Net of prepaid taxes [Member]
Income Taxes [Line Items]
Unrecognized tax benefits period end	$ 43,600
Operating lease obligations [Member]
Income Taxes [Line Items]
Other	48,600	$ 0
Operating lease assets [Member]
Income Taxes [Line Items]
Deferred Tax Liabilities, Leasing Arrangements	$ 46,400	$ 0

7. Stockholders' Equity (Detail

7. Stockholders' Equity (Details) - shares	1 Months Ended					12 Months Ended
	Nov. 30, 2019	Aug. 31, 2019	Jun. 30, 2019	May 31, 2019	Nov. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Class of Stock [Line Items]
Treasury Stock, Shares, Acquired	22,343	14,745	25,977	25,421	178,911
Common Class A [Member]
Class of Stock [Line Items]
Shares, Issued						24,966,000	24,884,000	24,679,000	24,454,000
Stock Issued During Period, Shares, Conversion of Convertible Securities						(24,000)	(30,000)	(34,000)
Stock Issued During Period, Shares, New Issues						58,000	175,000	191,000
Common Stock, Voting Rights						.10
Election Percentage for Board of Directors						25.00%
Common Class B [Member]
Class of Stock [Line Items]
Shares, Issued						5,090,000	5,096,000	5,108,000	5,124,000
Stock Issued During Period, Shares, Conversion of Convertible Securities						(24,000)	(30,000)	(34,000)
Stock Issued During Period, Shares, New Issues						18,000	18,000	18,000
Common Stock, Voting Rights						1
Election Percentage for Board of Directors						75.00%

7. Stockholders' Equity Treasur

7. Stockholders' Equity Treasury Shares (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended					12 Months Ended
	Nov. 30, 2019	Aug. 31, 2019	Jun. 30, 2019	May 31, 2019	Nov. 30, 2018	Dec. 31, 2019	Dec. 31, 2018
Equity, Class of Treasury Stock [Line Items]
Treasury Stock, Shares	281,636	259,293	244,548	218,571	193,150
Stock Repurchase Program, Remaining Authorized Repurchase Amount	$ 173.1	$ 181.1	$ 186.1	$ 193.7	$ 201.1
Stock Repurchase Program, Authorized Amount						$ 250
Treasury Stock, Shares, Acquired	22,343	14,745	25,977	25,421	178,911
Treasury Stock Acquired, Average Cost Per Share	$ 358.04	$ 339.05	$ 292.01	$ 291.70	$ 273.39
Treasury Class-A [Member]
Equity, Class of Treasury Stock [Line Items]
Stock Issued During Period, Shares, Treasury Stock Reissued						(118,910)
Treasury Class B [Member]
Equity, Class of Treasury Stock [Line Items]
Treasury Stock, Shares						0	917
Employee Stock [Member]
Equity, Class of Treasury Stock [Line Items]
Stock Issued During Period, Shares, Treasury Stock Reissued						(19,755)

8. Accumulated Other Comprehe_4

8. Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive (loss) income	$ (87,348)	$ (46,958)
Other comprehensive income, net of tax	(40,390)	(106,495)	$ 321,028
Foreign currency translation adjustments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive (loss) income	(72,400)	(35,500)	77,400
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	(36,500)	(112,900)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0	0
Other Comprehensive Income (Loss), Tax	(400)	0
Other comprehensive income, net of tax	(36,900)	(112,900)
Other Postretirement Benefit Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive (loss) income	(22,200)	(14,800)	(22,300)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	(10,000)	6,900
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	1,500	2,400
Other Comprehensive Income (Loss), Tax	1,100	(1,800)
Other comprehensive income, net of tax	(7,400)	7,500
Net Unrealized Investment Gain (Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive (loss) income	7,200	3,300	4,400
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	4,800	(1,400)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	(400)	300
Other Comprehensive Income (Loss), Tax	(500)	0
Other comprehensive income, net of tax	3,900	(1,100)
Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive (loss) income	(87,400)	(47,000)	$ 59,500
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	(41,700)	(107,400)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	1,100	2,700
Other Comprehensive Income (Loss), Tax	200	(1,800)
Other comprehensive income, net of tax	$ (40,400)	$ (106,500)

8. Accumulated Other Comprehe_5

8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Selling, general and administrative expense	$ (824,625)	$ (834,783)	$ (806,790)
Realized Investment Gains (Losses)	1,500	1,600	$ 100
Other Postretirement Benefit Plan [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Selling, general and administrative expense	1,500	2,400
Net Unrealized Investment Gain (Loss) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Realized Investment Gains (Losses)	$ 400	$ (300)

9. Share-based Compensation (De

9. Share-based Compensation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Exercise of Option, Tax Benefit	$ 5,400,000	$ 5,400,000	$ 6,300,000
Share-based Compensation Expense	35,600,000	27,800,000	23,400,000
Share-based Payment Arrangement, Expense, Tax Benefit	$ 5,600,000	$ 4,400,000	5,800,000
2011 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares Authorized	1,300,000
Stock Option and Award Plans [Member] | Incentive Award Plan 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares Authorized	2,095,049
Number of Shares Available for Grant	1,507,489
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Remaining Contractual Term (in years) - Outstanding	4 years 9 months 3 days
Aggregate Intrinsic Value (in millions) - Outstanding	$ 71.6
Options - Weighted-Average Exercise Price	$ 162.23	$ 138.81
Options Granted - Weighted Average Exercise Price	328.48
Options Exercised - Weighted Average Exercise Price	$ 98
Options Granted Term	P10Y
Options Forfeitured/expired - Weighted Average Exercise Price	$ 231.71
Options - Shares Vested and Expected to Vest	94,172
Options Vested and Expected to Vest - Weighted Average Exercise Price	$ 273.93
Options Vested and Expected to Vest - Weighted Average Remaining Contractual Term (in years)	8 years 5 months 12 days
Options Vested and Expected to Vest - Aggregate Intrinsic Value (in millions)	$ 9.1
Weighted Average Exercise Price - Options Exercisable	$ 120.22
Weighted Average Remaining Contractual Term (in years) - Exercisable	3 years 5 months 15 days
Options Exercisable Aggregate Intrinsic Value (in millions)	$ 62.5
Options, Exercises in Period, Total Intrinsic Value	12,000,000	$ 8,000,000	10,000,000
Cash Received from Exercise of Stock Options	2,600,000	$ 500,000	$ 1,600,000
Total unrecognized compensation cost from stock options	$ 7,000,000
Options Number Exercisable	250,350
Options Vesting Period	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	20.00%
Weighted average fair value of options granted, period for recognition	3 years
Expected Volatility	22.00%	22.00%	20.00%
Risk Free Interest Rate	1.69%	2.85%	1.87%
Expected life (in years)	7 years 6 months	7 years 7 months 6 days	7 years 2 months 12 days
Expected dividend	$ 0	$ 0	$ 0
Weighted average fair value of options granted	$ 93.96	$ 105.94	$ 58.65
Expected dividend yield	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding beginning of period	373,640
Options - Shares Granted	34,672
Options - Shares Exercised	(55,490)
Options - Shares Forfeitures/expired	(8,300)
Outstanding end of period	344,522	373,640
Employee Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares Available for Grant	599,531
Cash Received from Exercise of Stock Options	$ 14,300,000	$ 13,600,000	$ 13,000,000
Stock Issued During Period, Shares, Employee Stock Purchase Plans	58,717	63,464	74,409
Employee Contribution Rate - Maximum	10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount	$ 25,000
Employee Purchase Price Discount from Market Price	85.00%
Expected Volatility	31.00%	27.00%	19.00%
Risk Free Interest Rate	2.25%	1.82%	0.83%
Expected life (in years)	2 months 26 days	2 months 26 days	2 months 26 days
Expected dividend	$ 0	$ 0	$ 0
Expected dividend yield	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased	$ 60.39	$ 55.04	$ 38.86
Stock Award Plans [Member] | Incentive Award Plan 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Vesting Period	5 years

9. Share-based Compensation Res

9. Share-based Compensation Restricted Stock (Details) - Restricted Stock Units (RSUs) [Member] - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$ 44.8	$ 40	$ 27.7
Total unrecognized compensation cost from restricted stock	$ 119.5
Nonvested shares - Weighted Average Grant Date Fair Value	$ 279.14	$ 235.58
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Outstanding beginning of period	474,400
Restricted Stock Units Granted	174,782
Restricted Stock Units - Vested	(134,525)
Restricted Stock Units - Forfeited	(44,715)
Outstanding end of period	469,942	474,400
Weighted Average Grant Date Fair Value - Granted	$ 332.38
Restricted Stock Units Vested - Weighted-Average Grant-Date Fair Value	206.44
Resticted Stock Units Cancelled/forfeited - Weighted-Average Grant-Date Fair Value	$ 243.76
Weighted Average Remaining Contractual Term (in years)	2 years 29 days
Resticted Stock Units Outstanding Aggregate Intrinsic Value (in millions)	$ 173.9
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	3 years

10. Other Income and Expense_2

10. Other Income and Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Interest and investment income	$ (30,500)	$ (26,600)	$ (19,100)
Net realized gains on investments	(1,500)	(1,600)	(100)
Other-than-temporary impairment losses on investments	5,800	800	7,000
Gain on sale of land	0	(4,100)	0
Gain on divestiture of product line	0	(5,100)	0
Other Expense	100	0	1,500
Other (income) expense, net	$ (26,094)	$ (36,593)	$ (10,697)

11. Supplemental Cash Flow I_3

11. Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Other Significant Noncash Transactions [Line Items]
Net Income (Loss) Attributable to Parent	$ 553,500	$ (258,800)	$ 598,800	$ 865,200	$ (828,500)	$ 269,300	$ 268,000	$ 656,800	$ 1,758,675	$ 365,614	$ 122,249
Depreciation and amortization									134,200	138,100	148,700
Reduction in the carrying amount of right-of-use assets									40,300	0	0
Share-based compensation									35,600	27,800	23,400
Gains on disposition of securities									(1,500)	(1,600)	(100)
Other than Temporary Impairment Losses on Investments									5,800	800	7,000
Changes in fair market value of equity securities									(2,031,000)	(606,200)	0
Losses on dispositions of fixed assets									1,200	2,000	8,100
Gain on sale of land									0	(4,100)	0
Gain on divestiture of product line									0	5,100	0
Payments for operating lease liabilities									38,600	0	0
Changes in fair value of contingent consideration									(1,600)	(6,200)	(18,100)
Decrease (increase) in accounts receivable, net									1,600	59,700	(64,100)
Decrease (increase) in inventories, net									24,200	(12,900)	(47,700)
Decrease (increase) in Other Current Assets									61,800	(15,300)	(35,700)
Increase (decrease) in accounts payable and other current liabilities									10,600	(45,600)	7,800
Decrease in Income Taxes Payable									(4,200)	(20,900)	(22,400)
Increase (decrease) in deferred income taxes									450,200	120,900	(82,000)
(Increase) decrease in other long term assets									(1,700)	1,100	2,300
Increase (decrease) in Other Long Term Liabilities									13,400	(10,000)	38,100
Impairment losses on goodwill and long-lived assets					$ 292,500				0	292,513	11,506
Increase (Decrease) in Other Operating Assets and Liabilities, Net									1,100	(4,900)	(5,100)
Net cash provided by operating activities									457,897	285,494	104,137
Noncash purchased property, plant and equipment									8,100	5,700	0
Noncash Purchased Marketable Securities and Investments									1,400	800	2,800
Noncash or Part Noncash Acquisition, Accounts Receivable Acquired									$ 1,300	$ 0	$ 300

12. Commitments & Contingent _3

12. Commitments & Contingent Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Post-Employment Benefits Liability	$ 3.5	$ 3.1
Recorded Unconditional Purchase Obligation	118.4
Recorded Unconditional Purchase Obligation Due in Next Twelve Months	5.2
Recorded Unconditional Purchase Obligation Due in Second Year	12.8
Recorded Unconditional Purchase Obligation Due in Third Year	4.5
Recorded Unconditional Purchase Obligation Due in Fourth Year	4.3
Recorded Unconditional Purchase Obligation Due in Fifth Year	3.3
Recorded Unconditional Purchase Obligation Due after Fifth Year	88.3
Unrecorded Unconditional Purchase Obligation	35.8
Unrecorded Unconditional Purchase Obligation, Due in Twelve Months	34
Unrecorded Unconditional Purchase Obligation, Due within Two Years	1
Unrecorded Unconditional Purchase Obligation, Due within Three Years	0.2
Unrecorded Unconditional Purchase Obligation, Due within Four Years	0.2
Unrecorded Unconditional Purchase Obligation, Due within Five Years	0.2
Unrecorded Unconditional Purchase Obligation, Due after Five Years	0.2
Letters of Credit Outstanding Amount	$ 4.2
Employees Covered By Collective Bargaining Agreements U.S., Percentage	7.00%
UNITED STATES
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Entity Number of Employees	3,180

12. Commitments & Contingent _4

12. Commitments & Contingent Liabilities Period Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Contribution expense	$ 16.1	$ 15.9	$ 16

12. Commitments & Contingent _5

12. Commitments & Contingent Liabilities Pensions (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	1.10%	0.80%	0.90%
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	0.50%	1.10%
Defined Benefit Plan, Benefit Obligation	$ 153.8	$ 137.3	$ 136.6
Defined Benefit Plan, Service Cost	6.9	7.5	6.5
Defined Benefit Plan, Interest Cost	1.5	1.1	1.1
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	3.5	3.1
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)	11.9	(5.4)
Defined Benefit Plan, Benefit Obligation, Benefits Paid	(2.1)	(3.1)
Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment	0.2	(0.5)
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement	(3.8)	0
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)	(1.6)	(2)
Defined Benefit Plan, Plan Assets, Amount	72.3	66.9	61.7
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)	0.9	0.3
Defined Benefit Plan, Plan Assets, Contributions by Employer	4.7	4
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	3.8	3.1
Defined Benefit Plan, Plan Assets, Benefits Paid	(0.8)	(1.5)
Defined Benefit Plan, Plan Assets, Payment for Settlement	(3.8)	0
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)	0.6	(0.7)
Defined Benefit Plan, Funded (Unfunded) Status of Plan	(81.5)	(70.4)
Liability, Defined Benefit Plan, Current	(1.1)	(1.1)
Liability, Defined Benefit Plan, Noncurrent	(80.4)	(69.3)
Liability, Defined Benefit Plan	(81.5)	(70.4)
Defined Benefit Plan, Expected Return (Loss) on Plan Assets	(1.2)	(1.1)	(1.1)
Defined Benefit Plan, Amortization of Gain (Loss)	1	1.3	1.4
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	0	0.1	0
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement	0.9	0	1.2
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)	$ 9.1	$ 8.9	$ 9.1
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase	1.70%	1.80%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets	1.80%	1.80%	1.90%

13. Legal Proceedings Legal Pro

13. Legal Proceedings Legal Proceedings (Details) - USD ($)	Feb. 26, 2019	Dec. 31, 2018
Legal Proceedings [Abstract]
Loss Contingency, Damages Sought, Value		$ 10,920,000
Litigation Settlement Interest		$ 141,608
Subsequent Event [Line Items]
Loss Contingency Accrual, Period Increase (Decrease)	$ (2,960,000)
Loss Contingency, Damages Awarded, Value	$ 7,960,000

14. Segment Reporting (Details)

14. Segment Reporting (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Segment Reporting Information [Line Items]
Number Of Products And Services	9,000
Net sales	$ 2,311,700	$ 2,289,400	$ 2,160,200
Interest expense	23,416	23,962	23,014
Depreciation and amortization	134,200	138,100	148,700
Segment profit	229,661	(103,341)	119,250
Total assets	8,008,859	5,611,068
Payments to Acquire Property, Plant, and Equipment	98,532	129,825	111,332
Life Science [Member]
Segment Reporting Information [Line Items]
Net sales	885,900	861,700	785,200
Interest expense	7,400	7,200	7,000
Depreciation and amortization	29,400	34,100	36,200
Segment profit	72,100	28,700	(9,900)
Total assets	496,100	450,200
Payments to Acquire Property, Plant, and Equipment	16,600	36,700
Clinical Diagnostics [Member]
Segment Reporting Information [Line Items]
Net sales	1,412,000	1,411,800	1,360,800
Interest expense	15,900	16,700	14,900
Depreciation and amortization	71,700	72,000	80,200
Segment profit	148,500	(145,700)	114,800
Total assets	1,075,800	949,000
Payments to Acquire Property, Plant, and Equipment	58,900	60,500
All Other Segments [Member]
Segment Reporting Information [Line Items]
Net sales	13,800	15,900	14,200
Interest expense	100	100	0
Depreciation and amortization	900	500	0
Segment profit	(1,500)	200	$ 1,400
Total assets	9,200	5,900
Payments to Acquire Property, Plant, and Equipment	$ 600	$ 500

14. Segment Information Segment

14. Segment Information Segment Profit Reconciliation (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Goodwill, Impairment Loss		$ 0	$ 282,000
Income before income taxes		2,261,081	512,659	$ 97,805
Unrealized Gain on Securities	$ 646,000	2,030,987	606,230	0
Operating Segments [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes		219,100	(116,800)	106,300
Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Unrealized Gain on Securities		2,031,000	606,200	0
Corporate, Non-Segment [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes		(12,900)	(10,400)	(10,100)
Foreign Currency Gain (Loss) [Member] | Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes		(2,200)	(2,900)	(9,100)
Other Nonoperating Income (Expense) [Member] | Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes		26,100	36,600	$ 10,700
Clinical Diagnostics [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Goodwill, Impairment Loss		$ 0	$ 276,100

14. Segment Information Segme_2

14. Segment Information Segment Asset Reconciliation (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	$ 8,008,859	$ 5,611,068
Operating Segments [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	1,581,100	1,405,100
Other Current Assets [Member] | Segment Reconciling Items [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	1,233,500	1,047,200
Property, Plant and Equipment and Operating lease right-of-use assets excluding segment specific [Member] | Segment Reconciling Items [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	66,800	79,900
Goodwill [Member] | Segment Reconciling Items [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	264,100	219,800
Other Noncurrent Assets [Member] | Segment Reconciling Items [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	$ 4,863,400	$ 2,859,100

14. Segment Information Segme_3

14. Segment Information Segment Information by Geographical Location (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Segment Reporting Information [Line Items]
Net sales	$ 2,311.7	$ 2,289.4	$ 2,160.2
Other assets, property, plant and equipment, net and Operating lease right-of-use assets	731.2	530.1
Europe [Member]
Segment Reporting Information [Line Items]
Net sales	770.3	792	758.5
Other assets, property, plant and equipment, net and Operating lease right-of-use assets	198.3	129.1
Asia [Member]
Segment Reporting Information [Line Items]
Net sales	505	495.5	461.3
Other assets, property, plant and equipment, net and Operating lease right-of-use assets	51.5	20.7
UNITED STATES
Segment Reporting Information [Line Items]
Net sales	899.1	863.6	800.2
Other assets, property, plant and equipment, net and Operating lease right-of-use assets	468.7	369.2
Other (primarily Canada and Latin America) [Member]
Segment Reporting Information [Line Items]
Net sales	137.3	138.3	$ 140
Other assets, property, plant and equipment, net and Operating lease right-of-use assets	$ 12.7	$ 11.1

15. Restructuring Costs (Detail

15. Restructuring Costs (Details) - USD ($) $ in Millions	12 Months Ended			13 Months Ended	19 Months Ended	25 Months Ended	44 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Document Fiscal Year Focus	2019
European Reorganization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	$ (0.1)	$ (0.2)	$ 0.5
Restructuring Charges							$ 12.7
Restructuring Reserve	0	1.6	6.3	$ 0	$ 0	$ 0	0
Payments for Restructuring	(0.8)	(4.4)
Restructuring Reserve, Translation and Other Adjustment	(0.7)	0
Restructuring Reserve, Foreign Currency Translation (Gain) Loss	0	(0.1)
European Reorganization [Member] | Cost of Goods and Service Benchmark [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	(0.1)	(0.1)	(0.2)
European Reorganization [Member] | Selling, General and Administrative Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	0	(0.1)	0.7
European Reorganization [Member] | Life Science [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	0	(0.1)
Restructuring Reserve	0	0.6	2.2	0	0	0	0
Payments for Restructuring	(0.3)	(1.5)
Restructuring Reserve, Translation and Other Adjustment	(0.3)	0
Restructuring Reserve, Foreign Currency Translation (Gain) Loss	0	0
European Reorganization [Member] | Clinical Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	(0.1)	(0.1)
Restructuring Reserve	0	1	4.1	0	0	0	0
Payments for Restructuring	(0.5)	(2.9)
Restructuring Reserve, Translation and Other Adjustment	(0.4)	0
Restructuring Reserve, Foreign Currency Translation (Gain) Loss	0	(0.1)
Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges				4
Facility Closing [Member] | Clinical Diagnostics [Member] | Other Operating Income (Expense) [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	0
Restructuring Charges		0.2
Facility Closing [Member] | Clinical Diagnostics [Member] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	(0.1)
Restructuring Charges		3.9
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	(0.4)	0.3
Restructuring Charges	0	5.8
Restructuring Reserve	3.2	11.5	14.1	3.2	3.2	3.2	3.2
Payments for Restructuring	(7.7)	(8.4)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss	(0.2)	(0.3)
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Cost of Goods and Service Benchmark [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	(0.3)
Restructuring Charges		5.4	2.3
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Selling, General and Administrative Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	0
Restructuring Charges		0.4	3.3
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Research and Development Expense [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	0.1
Restructuring Charges		0.3	15.5
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Accounts Payable and Accrued Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	1.8			1.8	1.8	1.8	1.8
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Other Current Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	0.2			0.2	0.2	0.2	0.2
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Other Noncurrent Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	1.2			1.2	1.2	1.2	1.2
Termination of a Diagnostics Research and Development Project [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges						21.4
Termination of a Diagnostics Research and Development Project [Member] | Clinical Diagnostics [Member] | Other Operating Income (Expense) [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	0	(0.1)
Restructuring Charges			10.1
Termination of a Diagnostics Research and Development Project [Member] | Clinical Diagnostics [Member] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	(0.1)	0.4
Restructuring Charges			$ 11
European and North American Reorganization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	25.3
Restructuring Reserve	25.3	0		25.3	25.3	25.3	25.3
Payments for Restructuring	(1.1)
Restructuring Reserve, Translation and Other Adjustment	0.7
Restructuring Reserve, Foreign Currency Translation (Gain) Loss	0.4
European and North American Reorganization [Member] | Cost of Goods and Service Benchmark [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	4.8
European and North American Reorganization [Member] | Selling, General and Administrative Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	14.4
European and North American Reorganization [Member] | Research and Development Expense [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	6.1
European and North American Reorganization [Member] | Life Science [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	6.2
Restructuring Reserve	6.2	0		6.2	6.2	6.2	6.2
Payments for Restructuring	(0.4)
Restructuring Reserve, Translation and Other Adjustment	0.3
Restructuring Reserve, Foreign Currency Translation (Gain) Loss	0.1
European and North American Reorganization [Member] | Clinical Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	19.1
Restructuring Reserve	19.1	0		$ 19.1	19.1	$ 19.1	$ 19.1
Payments for Restructuring	(0.7)
Restructuring Reserve, Translation and Other Adjustment	0.4
Restructuring Reserve, Foreign Currency Translation (Gain) Loss	0.3
GERMANY | Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	$ (0.3)
Restructuring Charges		$ 1.7			$ 1.4

16. Leases (Details)

16. Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Lessee, Lease, Description [Line Items]
Unrecorded Unconditional Purchase Obligation	$ 1,600
Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract	4 years
Deferred Tax Assets, Other	$ 26,000	$ 27,100
U.S.	1,034,000	363,400	$ 72,800
Operating Leases, Rent Expense, Net		47,400	$ 43,600
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year	41,000
Finance Lease, Liability, Payments, Remainder of Fiscal Year	$ 1,100
Operating Lease, Weighted Average Remaining Lease Term	9 years
Property, Plant and Equipment, Gross	$ 1,382,172	1,326,829
Operating lease right-of-use asset	201,868	0
Operating Lease, Payments	47,200
Capital Leases, Future Minimum Payments Due in Three Years		500
Operating Leases, Future Minimum Payments Due, Next Twelve Months		44,400
Operating Leases, Future Minimum Payments, Due in Two Years		37,800
Operating leases, due in three years		27,400
Operating Lease, Cost	51,400
Finance Lease, Right-of-Use Asset, Amortization	600
Finance Lease, Interest Expense	900
Finance Lease Cost	1,500
Sublease Income	3,000
Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals		17,800
Operating Leases, Future Minimum Payments, Due in Four Years		19,700
Operating Leases, Future Minimum Payments, Due in Five Years		13,900
Operating Leases, Future Minimum Payments, Due Thereafter		25,600
Capital Leases, Future Minimum Payments Due, Next Twelve Months		500
Capital Leases, Future Minimum Payments Due in Two Years		200
Capital Leases, Future Minimum Payments Due in Four Years		400
Capital Leases, Future Minimum Payments Due in Five Years		400
Capital Leases, Future Minimum Payments Due Thereafter		9,900
Finance Lease, Interest Payment on Liability	900
Finance Lease, Principal Payments	600
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	28,700
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability	200
Current operating lease liabilities	35,365	0
Operating lease liabilities	176,018	0
Less: accumulated depreciation and amortization	(882,833)	(818,139)
Current maturities of long-term debt and notes payable	500
Finance Lease, Liability, Noncurrent	11,200
Property, plant and equipment, net	499,339	508,690
Operating Lease, Liability	$ 211,400
Finance Lease, Weighted Average Remaining Lease Term	18 years
Operating Lease, Weighted Average Discount Rate, Percent	4.20%
Finance Lease, Weighted Average Discount Rate, Percent	6.50%
Lessee, Operating Lease, Liability, Payments, Due Year Two	$ 35,800
Finance Lease, Liability, Payments, Due Year Two	1,300
Lessee, Operating Lease, Liability, Payments, Due Year Three	28,600
Finance Lease, Liability, Payments, Due Year Three	1,200
Lessee, Operating Lease, Liability, Payments, Due Year Four	24,500
Finance Lease, Liability, Payments, Due Year Four	1,100
Lessee, Operating Lease, Liability, Payments, Due Year Five	21,800
Finance Lease, Liability, Payments, Due Year Five	1,100
Lessee, Operating Lease, Liability, Payments, Due after Year Five	103,700
Finance Lease, Liability, Payments, Due after Year Five	15,200
Lessee, Operating Lease, Liability, Payments, Due	255,400
Finance Lease, Liability, Payment, Due	21,000
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	(44,000)
Finance Lease, Liability, Undiscounted Excess Amount	(9,300)
Finance Lease, Liability	$ 11,700
Maximum [Member]
Lessee, Lease, Description [Line Items]
Lessee Operating And Finance Leases Remaining Lease Term	19 years
Minimum [Member]
Lessee, Lease, Description [Line Items]
Lessee Operating And Finance Leases Remaining Lease Term	1 year
Finance Lease [Member]
Lessee, Lease, Description [Line Items]
Property, Plant and Equipment, Gross	$ 11,400
Less: accumulated depreciation and amortization	(4,200)
Property, plant and equipment, net	7,200
Operating lease obligations [Member]
Lessee, Lease, Description [Line Items]
Deferred Tax Assets, Other	$ 48,600	$ 0

17. Quarterly Financial Data (D

17. Quarterly Financial Data (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Quantifying Misstatement in Current Year Financial Statements [Line Items]
Unrealized Gain on Securities	$ 646,000								$ 2,030,987	$ 606,230	$ 0
Net sales	624,500	$ 560,600	$ 572,600	$ 554,000	$ 616,900	$ 545,100	$ 575,900	$ 551,500	2,311,659	2,289,415	2,160,153
Operating Income (Loss)									229,661	(103,341)	119,250
Cost of Goods and Services Sold									1,054,663	1,066,264	972,450
Gross profit	330,400	307,000	307,800	311,800	332,600	286,700	301,700	302,200	1,256,996	1,223,151	1,187,703
Selling, general and administrative expense									824,625	834,783	806,790
Research and development expense									202,710	199,196	250,157
Unrealized Loss on Securities		390,600			814,100
Net Income (Loss) Attributable to Parent	$ 553,500	$ (258,800)	$ 598,800	$ 865,200	$ (828,500)	$ 269,300	$ 268,000	$ 656,800	$ 1,758,675	$ 365,614	$ 122,249
Earnings Per Share, Basic	$ 18.50	$ (8.68)	$ 20.08	$ 29.03	$ (27.73)	$ 9.02	$ 8.99	$ 22.05	$ 58.93	$ 12.25	$ 4.12
Earnings Per Share, Diluted	$ 18.31	$ (8.68)	$ 19.86	$ 28.74	$ (27.73)	$ 8.89	$ 8.87	$ 21.77	$ 58.27	$ 12.10	$ 4.07
Income Tax Expense (Benefit)									$ (502,406)	$ (147,045)	$ 24,444
Impairment losses on goodwill and long-lived assets					$ 292,500				$ 0	$ 292,513	$ 11,506

18. Subsequent Event (Details)

18. Subsequent Event (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Mar. 31, 2019
Subsequent Event [Line Items]
Business Combination, Consideration Transferred	$ 4.2	$ 60	$ 20

Schedule II - Valuation and Q_2

Schedule II - Valuation and Qualifying Accoutns (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease)	$ 0	$ 4,413	$ (47)
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation Allowances and Reserves, Balance Period Start	70,769	66,356	66,403
Deductions	(3,579)	0	0
Valuation Allowances and Reserves, Balance Period End	67,190	70,769	66,356
SEC Schedule, 12-09, Allowance, Credit Loss [Member]
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease)	(1,240)
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense		11,527	11,174
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation Allowances and Reserves, Balance Period Start	26,713	25,549	23,367
Deductions	(5,268)	(10,363)	(8,992)
Valuation Allowances and Reserves, Balance Period End	$ 20,205	$ 26,713	$ 25,549

Uncategorized Items - a10k12311

Label	Element	Value
Retained Earnings [Member]
Equity Securities without Readily Determinable Fair Value, Amount	us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	$ 1,543,747,000
AOCI Attributable to Parent [Member]
Equity Securities without Readily Determinable Fair Value, Amount	us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	(679,257,000)
Accounting Standards Update 2014-09 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	(136,000)
Accounting Standards Update 2016-16 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ (17,591,000)